WO2010032200A1 - Amide compounds useful in therapy - Google Patents
Amide compounds useful in therapy Download PDFInfo
- Publication number
- WO2010032200A1 WO2010032200A1 PCT/IB2009/054038 IB2009054038W WO2010032200A1 WO 2010032200 A1 WO2010032200 A1 WO 2010032200A1 IB 2009054038 W IB2009054038 W IB 2009054038W WO 2010032200 A1 WO2010032200 A1 WO 2010032200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrazole
- carboxamide
- cyanophenyl
- isopropyl
- cyclopropyl
- Prior art date
Links
- -1 Amide compounds Chemical class 0.000 title claims description 131
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 606
- 238000000034 method Methods 0.000 claims abstract description 197
- 239000000203 mixture Substances 0.000 claims abstract description 130
- 150000003839 salts Chemical class 0.000 claims abstract description 62
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 239000012453 solvate Substances 0.000 claims abstract description 39
- 201000009273 Endometriosis Diseases 0.000 claims abstract description 37
- 125000001424 substituent group Chemical group 0.000 claims abstract description 32
- 201000010260 leiomyoma Diseases 0.000 claims abstract description 28
- 206010046798 Uterine leiomyoma Diseases 0.000 claims abstract description 26
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 26
- 150000002367 halogens Chemical class 0.000 claims abstract description 25
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 89
- 229920006395 saturated elastomer Polymers 0.000 claims description 34
- 208000024891 symptom Diseases 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 21
- 208000000450 Pelvic Pain Diseases 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 102000003998 progesterone receptors Human genes 0.000 claims description 15
- 108090000468 progesterone receptors Proteins 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 208000007106 menorrhagia Diseases 0.000 claims description 11
- 208000005641 Adenomyosis Diseases 0.000 claims description 10
- 208000004483 Dyspareunia Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 201000009274 endometriosis of uterus Diseases 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 230000002611 ovarian Effects 0.000 claims description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 9
- 210000000481 breast Anatomy 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 206010014733 Endometrial cancer Diseases 0.000 claims description 8
- 230000008901 benefit Effects 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- VCVJJXWOLOJNJU-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(2-hydroxy-2-methylpropyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(O)(C)CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 VCVJJXWOLOJNJU-UHFFFAOYSA-N 0.000 claims description 5
- WZKANHVIGHAWDK-IBGZPJMESA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(3s)-1-propanoylpyrrolidin-3-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1N(C(=O)CC)CC[C@@H]1NC(=O)C(N(N=C1C=2C=CC(=CC=2)C#N)C(C)C)=C1C1CC1 WZKANHVIGHAWDK-IBGZPJMESA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- YIAGHWLJXSQTNF-UHFFFAOYSA-N 4-cyano-5-(4-cyanophenyl)-n,2-di(propan-2-yl)pyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC(C)C)=C(C#N)C(C=2C=CC(=CC=2)C#N)=N1 YIAGHWLJXSQTNF-UHFFFAOYSA-N 0.000 claims description 4
- VDSNWLNCUOGZBC-UHFFFAOYSA-N 4-cyano-5-(4-cyanophenyl)-n-ethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NCC)=C(C#N)C(C=2C=CC(=CC=2)C#N)=N1 VDSNWLNCUOGZBC-UHFFFAOYSA-N 0.000 claims description 4
- UMIUTNHZINBZSD-LBPRGKRZSA-N 5-(4-cyanophenyl)-2-cyclobutyl-n-[(2s)-2-hydroxypropyl]-4-methylpyrazole-3-carboxamide Chemical compound C[C@H](O)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 UMIUTNHZINBZSD-LBPRGKRZSA-N 0.000 claims description 4
- MPOJUMRSSPODEY-NSHDSACASA-N 5-(4-cyanophenyl)-2-cyclopropyl-n-[(2s)-2-hydroxypropyl]-4-methylpyrazole-3-carboxamide Chemical compound C[C@H](O)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 MPOJUMRSSPODEY-NSHDSACASA-N 0.000 claims description 4
- PHTWLGFHZKPPSJ-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-(3,3-difluorocyclobutyl)-n-ethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCC)=C1C1CC(F)(F)C1 PHTWLGFHZKPPSJ-UHFFFAOYSA-N 0.000 claims description 4
- LSKWDBADKXIQFN-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n,2-di(propan-2-yl)pyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NC(C)C)=C1C1CC1 LSKWDBADKXIQFN-UHFFFAOYSA-N 0.000 claims description 4
- ZZWKFOCGDWCDDX-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(1-methylsulfonylazetidin-3-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1N(S(C)(=O)=O)CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 ZZWKFOCGDWCDDX-UHFFFAOYSA-N 0.000 claims description 4
- FCLJBNPOXFMTPP-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-ethyl-n,2-di(propan-2-yl)pyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC(C)C)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 FCLJBNPOXFMTPP-UHFFFAOYSA-N 0.000 claims description 4
- VKBOJTQZXPRWSY-UHFFFAOYSA-N 5-(4-cyanophenyl)-n-(2-hydroxy-2-methylpropyl)-4-methyl-2-(oxolan-3-yl)pyrazole-3-carboxamide Chemical compound CC(O)(C)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCOC1 VKBOJTQZXPRWSY-UHFFFAOYSA-N 0.000 claims description 4
- WHQQUTRCBTUYPN-UHFFFAOYSA-N 5-(4-cyanophenyl)-n-cyclopropyl-4-ethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CCC=1C(C=2C=CC(=CC=2)C#N)=NN(C(C)C)C=1C(=O)NC1CC1 WHQQUTRCBTUYPN-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- BYHDNQBLRHQLBA-UHFFFAOYSA-N n-(1-acetylazetidin-3-yl)-5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1N(C(C)=O)CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 BYHDNQBLRHQLBA-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- SDZICSPVYMXOSB-UHFFFAOYSA-N 2-butan-2-yl-5-(4-cyanophenyl)-4-ethyl-n-(2-hydroxy-2-methylpropyl)pyrazole-3-carboxamide Chemical compound CCC1=C(C(=O)NCC(C)(C)O)N(C(C)CC)N=C1C1=CC=C(C#N)C=C1 SDZICSPVYMXOSB-UHFFFAOYSA-N 0.000 claims description 3
- QMOWKNTVESEZCI-ARLHGKGLSA-N 2-butan-2-yl-5-(4-cyanophenyl)-4-ethyl-n-[(2r)-2-hydroxypropyl]pyrazole-3-carboxamide Chemical compound CCC1=C(C(=O)NC[C@@H](C)O)N(C(C)CC)N=C1C1=CC=C(C#N)C=C1 QMOWKNTVESEZCI-ARLHGKGLSA-N 0.000 claims description 3
- QMOWKNTVESEZCI-KZUDCZAMSA-N 2-butan-2-yl-5-(4-cyanophenyl)-4-ethyl-n-[(2s)-2-hydroxypropyl]pyrazole-3-carboxamide Chemical compound CCC1=C(C(=O)NC[C@H](C)O)N(C(C)CC)N=C1C1=CC=C(C#N)C=C1 QMOWKNTVESEZCI-KZUDCZAMSA-N 0.000 claims description 3
- IEOCDBZXUUPNPG-UHFFFAOYSA-N 4-benzyl-5-(4-cyanophenyl)-n,2-di(propan-2-yl)pyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NC(C)C)=C1CC1=CC=CC=C1 IEOCDBZXUUPNPG-UHFFFAOYSA-N 0.000 claims description 3
- LGAQXDXWEYTAGV-UHFFFAOYSA-N 4-benzyl-5-(4-cyanophenyl)-n-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1CC1=CC=CC=C1 LGAQXDXWEYTAGV-UHFFFAOYSA-N 0.000 claims description 3
- OSKNGWSQLJMACL-UHFFFAOYSA-N 4-benzyl-5-(4-cyanophenyl)-n-ethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCC)=C1CC1=CC=CC=C1 OSKNGWSQLJMACL-UHFFFAOYSA-N 0.000 claims description 3
- YEWVTHULFRGMBO-UHFFFAOYSA-N 4-cyano-5-(4-cyanophenyl)-n-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1N=C(C=2C=CC(=CC=2)C#N)C(C#N)=C1C(=O)NC1CC1 YEWVTHULFRGMBO-UHFFFAOYSA-N 0.000 claims description 3
- QYDGVWGFJZRANB-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-4-methyl-n,2-di(propan-2-yl)pyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC(C)C)=C(C)C(C=2C=C(C)C(C#N)=CC=2)=N1 QYDGVWGFJZRANB-UHFFFAOYSA-N 0.000 claims description 3
- KTWAYRSCWRZRGZ-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-n,4-dimethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC)=C(C)C(C=2C=C(C)C(C#N)=CC=2)=N1 KTWAYRSCWRZRGZ-UHFFFAOYSA-N 0.000 claims description 3
- BGJBWNKGIONRMZ-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-n-(2-hydroxy-2-methylpropyl)-4-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC1=C(C(=O)NCC(C)(C)O)N(C(C)C)N=C1C1=CC=C(C#N)C(C)=C1 BGJBWNKGIONRMZ-UHFFFAOYSA-N 0.000 claims description 3
- LZIQYEQHLHOHMT-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-n-ethyl-4-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NCC)=C(C)C(C=2C=C(C)C(C#N)=CC=2)=N1 LZIQYEQHLHOHMT-UHFFFAOYSA-N 0.000 claims description 3
- UMIUTNHZINBZSD-GFCCVEGCSA-N 5-(4-cyanophenyl)-2-cyclobutyl-n-[(2r)-2-hydroxypropyl]-4-methylpyrazole-3-carboxamide Chemical compound C[C@@H](O)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 UMIUTNHZINBZSD-GFCCVEGCSA-N 0.000 claims description 3
- WJTRCVPTGKYBLV-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclopropyl-n-(cyclopropylmethyl)-4-methylpyrazole-3-carboxamide Chemical compound C1CC1CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 WJTRCVPTGKYBLV-UHFFFAOYSA-N 0.000 claims description 3
- MPOJUMRSSPODEY-LLVKDONJSA-N 5-(4-cyanophenyl)-2-cyclopropyl-n-[(2r)-2-hydroxypropyl]-4-methylpyrazole-3-carboxamide Chemical compound C[C@@H](O)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 MPOJUMRSSPODEY-LLVKDONJSA-N 0.000 claims description 3
- VQECVCDXYDUCNV-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-(3,3-difluorocyclobutyl)-n-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NC)=C1C1CC(F)(F)C1 VQECVCDXYDUCNV-UHFFFAOYSA-N 0.000 claims description 3
- OACGSIMESQKOCL-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-(2,2,2-trifluoroethyl)pyrazole-3-carboxamide Chemical compound FC(F)(F)CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 OACGSIMESQKOCL-UHFFFAOYSA-N 0.000 claims description 3
- WHUHOJGJYFZXDS-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-(3,3,3-trifluoropropyl)pyrazole-3-carboxamide Chemical compound FC(F)(F)CCNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 WHUHOJGJYFZXDS-UHFFFAOYSA-N 0.000 claims description 3
- VCFGQSOYEVGCLF-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-propylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCCC)=C1C1CC1 VCFGQSOYEVGCLF-UHFFFAOYSA-N 0.000 claims description 3
- JBODGSANAKZLOE-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(1-propanoylazetidin-3-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1N(C(=O)CC)CC1NC(=O)C(N(N=C1C=2C=CC(=CC=2)C#N)C(C)C)=C1C1CC1 JBODGSANAKZLOE-UHFFFAOYSA-N 0.000 claims description 3
- WUSZRFPVDRBEDT-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(2-methoxyethyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCCOC)=C1C1CC1 WUSZRFPVDRBEDT-UHFFFAOYSA-N 0.000 claims description 3
- VJQZKDYGAKVNHM-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(3-methoxypropyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCCCOC)=C1C1CC1 VJQZKDYGAKVNHM-UHFFFAOYSA-N 0.000 claims description 3
- OIAAHTXRBGPLJC-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(cyclopropylmethyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CC1CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 OIAAHTXRBGPLJC-UHFFFAOYSA-N 0.000 claims description 3
- RWJUUZFBLRWHGJ-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(1-methylpyrazol-4-yl)methyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1=NN(C)C=C1CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 RWJUUZFBLRWHGJ-UHFFFAOYSA-N 0.000 claims description 3
- UDVMXBBSEPROLV-HXUWFJFHSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(3r)-1-(2-methylpropanoyl)pyrrolidin-3-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1N(C(=O)C(C)C)CC[C@H]1NC(=O)C(N(N=C1C=2C=CC(=CC=2)C#N)C(C)C)=C1C1CC1 UDVMXBBSEPROLV-HXUWFJFHSA-N 0.000 claims description 3
- UDVMXBBSEPROLV-FQEVSTJZSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(3s)-1-(2-methylpropanoyl)pyrrolidin-3-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1N(C(=O)C(C)C)CC[C@@H]1NC(=O)C(N(N=C1C=2C=CC(=CC=2)C#N)C(C)C)=C1C1CC1 UDVMXBBSEPROLV-FQEVSTJZSA-N 0.000 claims description 3
- QXYUZNJWZVXGOS-INIZCTEOSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(3s)-2-oxooxolan-3-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound N([C@@H]1C(OCC1)=O)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 QXYUZNJWZVXGOS-INIZCTEOSA-N 0.000 claims description 3
- UMPUBZWZIUDOOM-GOSISDBHSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(6r)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-6-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound N([C@H]1CN2C=CN=C2C1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 UMPUBZWZIUDOOM-GOSISDBHSA-N 0.000 claims description 3
- UMPUBZWZIUDOOM-SFHVURJKSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(6s)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-6-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound N([C@@H]1CN2C=CN=C2C1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 UMPUBZWZIUDOOM-SFHVURJKSA-N 0.000 claims description 3
- QSMVRLNQTWKTDV-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[1-(1-methylpyrazol-4-yl)ethyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1=NN(C)C=C1C(C)NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 QSMVRLNQTWKTDV-UHFFFAOYSA-N 0.000 claims description 3
- OOJXSVJVUKKWLL-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[1-(2-methylpropanoyl)azetidin-3-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1N(C(=O)C(C)C)CC1NC(=O)C(N(N=C1C=2C=CC(=CC=2)C#N)C(C)C)=C1C1CC1 OOJXSVJVUKKWLL-UHFFFAOYSA-N 0.000 claims description 3
- AOHXXMCSOZRHPR-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-ethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCC)=C1C1CC1 AOHXXMCSOZRHPR-UHFFFAOYSA-N 0.000 claims description 3
- JHNKPVKQRMPQAS-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NC)=C1C1CC1 JHNKPVKQRMPQAS-UHFFFAOYSA-N 0.000 claims description 3
- QPVDZLPTLGDRPO-UHFFFAOYSA-N 5-(4-cyanophenyl)-n,2-dicyclopropyl-4-methylpyrazole-3-carboxamide Chemical compound C1CC1NC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 QPVDZLPTLGDRPO-UHFFFAOYSA-N 0.000 claims description 3
- FCDGFMMLLIREBJ-UHFFFAOYSA-N 5-(4-cyanophenyl)-n,4-dicyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 FCDGFMMLLIREBJ-UHFFFAOYSA-N 0.000 claims description 3
- YZDIBZSBRCJEEL-UHFFFAOYSA-N 5-(4-cyanophenyl)-n,4-diethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NCC)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 YZDIBZSBRCJEEL-UHFFFAOYSA-N 0.000 claims description 3
- OZSSUUDDOJZMMU-UHFFFAOYSA-N 5-(4-cyanophenyl)-n-cyclobutyl-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CCC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 OZSSUUDDOJZMMU-UHFFFAOYSA-N 0.000 claims description 3
- NNJMDXQZFHKCMQ-UHFFFAOYSA-N 5-(4-cyanophenyl)-n-cyclopropyl-4-(3,3-difluorocyclobutyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC(F)(F)C1 NNJMDXQZFHKCMQ-UHFFFAOYSA-N 0.000 claims description 3
- HFPWGPXJTGLOSR-UHFFFAOYSA-N 5-(4-cyanophenyl)-n-ethyl-4-methyl-2-(oxolan-3-yl)pyrazole-3-carboxamide Chemical compound CCNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCOC1 HFPWGPXJTGLOSR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- HOUFMPAPOZWTOF-UHFFFAOYSA-N n-(2-amino-2-methylpropyl)-5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(N)(C)CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 HOUFMPAPOZWTOF-UHFFFAOYSA-N 0.000 claims description 3
- XKBWGFIBNCHSGP-UHFFFAOYSA-N n-(azetidin-3-yl)-5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1NCC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 XKBWGFIBNCHSGP-UHFFFAOYSA-N 0.000 claims description 3
- SBGVKFIPMHCOIC-AWEZNQCLSA-N n-[(2s)-butan-2-yl]-5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)N[C@@H](C)CC)=C1C1CC1 SBGVKFIPMHCOIC-AWEZNQCLSA-N 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 2
- FFPYOXYDFNUAFY-UHFFFAOYSA-N 2-butan-2-yl-5-(4-cyanophenyl)-4-ethyl-n-methylpyrazole-3-carboxamide Chemical compound CCC1=C(C(=O)NC)N(C(C)CC)N=C1C1=CC=C(C#N)C=C1 FFPYOXYDFNUAFY-UHFFFAOYSA-N 0.000 claims description 2
- GPGOMDBNUDLLIK-UHFFFAOYSA-N 2-butan-2-yl-5-(4-cyanophenyl)-n,4-diethylpyrazole-3-carboxamide Chemical compound CCC(C)N1C(C(=O)NCC)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 GPGOMDBNUDLLIK-UHFFFAOYSA-N 0.000 claims description 2
- XRKVQHBODOBNNB-UHFFFAOYSA-N 2-butan-2-yl-5-(4-cyanophenyl)-n-(cyclopropylmethyl)-4-ethylpyrazole-3-carboxamide Chemical compound CCC(C)N1N=C(C=2C=CC(=CC=2)C#N)C(CC)=C1C(=O)NCC1CC1 XRKVQHBODOBNNB-UHFFFAOYSA-N 0.000 claims description 2
- COQQZKHXBCBTTJ-UHFFFAOYSA-N 2-butan-2-yl-5-(4-cyanophenyl)-n-cyclopropyl-4-ethylpyrazole-3-carboxamide Chemical compound CCC(C)N1N=C(C=2C=CC(=CC=2)C#N)C(CC)=C1C(=O)NC1CC1 COQQZKHXBCBTTJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- RRSUQXDTEZPRMH-UHFFFAOYSA-N 4-cyano-5-(4-cyanophenyl)-n-(cyclopropylmethyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1N=C(C=2C=CC(=CC=2)C#N)C(C#N)=C1C(=O)NCC1CC1 RRSUQXDTEZPRMH-UHFFFAOYSA-N 0.000 claims description 2
- XBTGKQAYTSXSFW-UHFFFAOYSA-N 4-cyano-5-(4-cyanophenyl)-n-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC)=C(C#N)C(C=2C=CC(=CC=2)C#N)=N1 XBTGKQAYTSXSFW-UHFFFAOYSA-N 0.000 claims description 2
- LRRUUZSCDWDGOP-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-4-cyclopropyl-n-[2-(methylamino)-2-oxoethyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C(C)=CC=1C1=NN(C(C)C)C(C(=O)NCC(=O)NC)=C1C1CC1 LRRUUZSCDWDGOP-UHFFFAOYSA-N 0.000 claims description 2
- QVADJKYRFUVAIF-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-n-cyclopropyl-4-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1N=C(C=2C=C(C)C(C#N)=CC=2)C(C)=C1C(=O)NC1CC1 QVADJKYRFUVAIF-UHFFFAOYSA-N 0.000 claims description 2
- QCNXVNKVIAVYEC-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclobutyl-n-cyclopropyl-4-methylpyrazole-3-carboxamide Chemical compound C1CC1NC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 QCNXVNKVIAVYEC-UHFFFAOYSA-N 0.000 claims description 2
- RDPAMRISSWIKCD-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclopropyl-n,4-dimethylpyrazole-3-carboxamide Chemical compound CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 RDPAMRISSWIKCD-UHFFFAOYSA-N 0.000 claims description 2
- UKMMKUYMOZCEHR-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclopropyl-n-ethyl-4-methylpyrazole-3-carboxamide Chemical compound CCNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 UKMMKUYMOZCEHR-UHFFFAOYSA-N 0.000 claims description 2
- YPYBHGOWHLTPSH-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-(1-pyrazol-1-ylpropan-2-yl)pyrazole-3-carboxamide Chemical compound C1CC1C=1C(C=2C=CC(=CC=2)C#N)=NN(C(C)C)C=1C(=O)NC(C)CN1C=CC=N1 YPYBHGOWHLTPSH-UHFFFAOYSA-N 0.000 claims description 2
- BQROTUNVXNXQFO-QGZVFWFLSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-[(3r)-pyrrolidin-3-yl]pyrazole-3-carboxamide Chemical compound N([C@H]1CNCC1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 BQROTUNVXNXQFO-QGZVFWFLSA-N 0.000 claims description 2
- BQROTUNVXNXQFO-KRWDZBQOSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-[(3s)-pyrrolidin-3-yl]pyrazole-3-carboxamide Chemical compound N([C@@H]1CNCC1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 BQROTUNVXNXQFO-KRWDZBQOSA-N 0.000 claims description 2
- ACRHATDPJUUOIQ-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(1,1-dioxothiolan-3-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CS(=O)(=O)CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 ACRHATDPJUUOIQ-UHFFFAOYSA-N 0.000 claims description 2
- SBTLHVUCPBSIBT-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(1-hydroxy-2-methylpropan-2-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound OCC(C)(C)NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 SBTLHVUCPBSIBT-UHFFFAOYSA-N 0.000 claims description 2
- UBXGKYILYOCVGB-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(2,2-dimethylpropyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)(C)CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 UBXGKYILYOCVGB-UHFFFAOYSA-N 0.000 claims description 2
- WCXVUYXIGPFOGB-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(2-cyclopropylethyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CC1CCNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 WCXVUYXIGPFOGB-UHFFFAOYSA-N 0.000 claims description 2
- KBORPXVRRGHOJB-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(2-oxopropyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(=O)CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 KBORPXVRRGHOJB-UHFFFAOYSA-N 0.000 claims description 2
- PNXMWRMYLRHPOU-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(cyclopropylmethyl)-n-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CC1CN(C)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 PNXMWRMYLRHPOU-UHFFFAOYSA-N 0.000 claims description 2
- PUHTUSWAWVREGY-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(oxan-3-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CCOCC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 PUHTUSWAWVREGY-UHFFFAOYSA-N 0.000 claims description 2
- GDFKDZQZHHFAQS-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(oxan-4-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1COCCC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 GDFKDZQZHHFAQS-UHFFFAOYSA-N 0.000 claims description 2
- PMFFJQNIINPWNE-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(oxolan-3-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1COCC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 PMFFJQNIINPWNE-UHFFFAOYSA-N 0.000 claims description 2
- PEWNLSMMUUAIKA-CYBMUJFWSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(2r)-2-hydroxypropyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NC[C@H](O)C)=C1C1CC1 PEWNLSMMUUAIKA-CYBMUJFWSA-N 0.000 claims description 2
- PEWNLSMMUUAIKA-ZDUSSCGKSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(2s)-2-hydroxypropyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NC[C@@H](O)C)=C1C1CC1 PEWNLSMMUUAIKA-ZDUSSCGKSA-N 0.000 claims description 2
- HHYYYIJQMLJIAH-MRXNPFEDSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(3r)-5-oxopyrrolidin-3-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound N([C@@H]1CC(=O)NC1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 HHYYYIJQMLJIAH-MRXNPFEDSA-N 0.000 claims description 2
- JMXMTVLYFLKDNA-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[2-(methylamino)-2-oxoethyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCC(=O)NC)=C1C1CC1 JMXMTVLYFLKDNA-UHFFFAOYSA-N 0.000 claims description 2
- VBPZGYPGYXZUHA-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[3-(2-oxopyrrolidin-1-yl)propyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CCC(=O)N1CCCNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 VBPZGYPGYXZUHA-UHFFFAOYSA-N 0.000 claims description 2
- PEZVHKVTOBJLHW-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-ethyl-n-(2-hydroxy-2-methylpropyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NCC(C)(C)O)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 PEZVHKVTOBJLHW-UHFFFAOYSA-N 0.000 claims description 2
- MKDVQMOTGWFXAS-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-methyl-2-(oxolan-3-yl)-n-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCOC1 MKDVQMOTGWFXAS-UHFFFAOYSA-N 0.000 claims description 2
- RDCCZYHLSAKEIS-UHFFFAOYSA-N 5-(4-cyanophenyl)-n-(cyclopropylmethyl)-4-ethyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CCC=1C(C=2C=CC(=CC=2)C#N)=NN(C(C)C)C=1C(=O)NCC1CC1 RDCCZYHLSAKEIS-UHFFFAOYSA-N 0.000 claims description 2
- RURICRZQHKXBKR-HKALDPMFSA-N 5-(4-cyanophenyl)-n-[(2s)-2-hydroxypropyl]-4-methyl-2-(oxolan-3-yl)pyrazole-3-carboxamide Chemical compound C[C@H](O)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCOC1 RURICRZQHKXBKR-HKALDPMFSA-N 0.000 claims description 2
- BRQAUCHSDOYGOA-UHFFFAOYSA-N C1N(C(O)=O)CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 Chemical compound C1N(C(O)=O)CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 BRQAUCHSDOYGOA-UHFFFAOYSA-N 0.000 claims description 2
- DCVZZGZHNOPNKF-UHFFFAOYSA-N OC(=O)C(C)(C)NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 Chemical compound OC(=O)C(C)(C)NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 DCVZZGZHNOPNKF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- QQTZVXXMBPURRW-UHFFFAOYSA-N n-(2-aminoethyl)-5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound NCCNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 QQTZVXXMBPURRW-UHFFFAOYSA-N 0.000 claims description 2
- WJAXQXCFEZCZRA-UHFFFAOYSA-N n-tert-butyl-5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)(C)NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 WJAXQXCFEZCZRA-UHFFFAOYSA-N 0.000 claims description 2
- RKTTWHVXTNYCEF-HXUWFJFHSA-N tert-butyl (3r)-3-[[5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carbonyl]amino]pyrrolidine-1-carboxylate Chemical compound N([C@H]1CN(CC1)C(=O)OC(C)(C)C)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 RKTTWHVXTNYCEF-HXUWFJFHSA-N 0.000 claims description 2
- RKTTWHVXTNYCEF-FQEVSTJZSA-N tert-butyl (3s)-3-[[5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carbonyl]amino]pyrrolidine-1-carboxylate Chemical compound N([C@@H]1CN(CC1)C(=O)OC(C)(C)C)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 RKTTWHVXTNYCEF-FQEVSTJZSA-N 0.000 claims description 2
- HSPGZCZZFFLAIW-ZDUSSCGKSA-N 5-(4-cyano-3-methylphenyl)-n-[(2s)-2-hydroxypropyl]-4-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC[C@@H](O)C)=C(C)C(C=2C=C(C)C(C#N)=CC=2)=N1 HSPGZCZZFFLAIW-ZDUSSCGKSA-N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- HSPGZCZZFFLAIW-CYBMUJFWSA-N 5-(4-cyano-3-methylphenyl)-n-[(2r)-2-hydroxypropyl]-4-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC[C@H](O)C)=C(C)C(C=2C=C(C)C(C#N)=CC=2)=N1 HSPGZCZZFFLAIW-CYBMUJFWSA-N 0.000 claims 1
- ZPSGDVZKRMFCMX-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(1-methyl-6-oxopiperidin-3-yl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CC(=O)N(C)CC1NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 ZPSGDVZKRMFCMX-UHFFFAOYSA-N 0.000 claims 1
- DYTPNQVJXMKNGA-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-(oxolan-2-ylmethyl)-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C1CCOC1CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 DYTPNQVJXMKNGA-UHFFFAOYSA-N 0.000 claims 1
- FEDQYUGKJRIKKB-GOSISDBHSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(3r)-1-methylsulfonylpyrrolidin-3-yl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound N([C@H]1CN(CC1)S(C)(=O)=O)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 FEDQYUGKJRIKKB-GOSISDBHSA-N 0.000 claims 1
- VZMRCHJLDZYEIR-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[2-(ethylamino)-2-oxoethyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NCC(=O)NCC)=C1C1CC1 VZMRCHJLDZYEIR-UHFFFAOYSA-N 0.000 claims 1
- AIUUGQUUYHIIFP-CYBMUJFWSA-N 5-(4-cyanophenyl)-4-ethyl-n-[(2r)-2-hydroxypropyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC[C@@H](C)O)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 AIUUGQUUYHIIFP-CYBMUJFWSA-N 0.000 claims 1
- AIUUGQUUYHIIFP-ZDUSSCGKSA-N 5-(4-cyanophenyl)-4-ethyl-n-[(2s)-2-hydroxypropyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC[C@H](C)O)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 AIUUGQUUYHIIFP-ZDUSSCGKSA-N 0.000 claims 1
- RURICRZQHKXBKR-ZGTOLYCTSA-N 5-(4-cyanophenyl)-n-[(2r)-2-hydroxypropyl]-4-methyl-2-(oxolan-3-yl)pyrazole-3-carboxamide Chemical compound C[C@@H](O)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCOC1 RURICRZQHKXBKR-ZGTOLYCTSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 267
- 230000008569 process Effects 0.000 abstract description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 190
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 138
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 128
- 238000005160 1H NMR spectroscopy Methods 0.000 description 106
- 239000000243 solution Substances 0.000 description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 73
- 230000002829 reductive effect Effects 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 47
- 229940093499 ethyl acetate Drugs 0.000 description 46
- 235000019439 ethyl acetate Nutrition 0.000 description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 41
- 238000004128 high performance liquid chromatography Methods 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 30
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000009472 formulation Methods 0.000 description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- 239000000284 extract Substances 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- 229940002612 prodrug Drugs 0.000 description 24
- 239000000651 prodrug Substances 0.000 description 24
- 239000000186 progesterone Substances 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 239000000556 agonist Substances 0.000 description 20
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 20
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 229960003387 progesterone Drugs 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 11
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 9
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 9
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229940123788 Progesterone receptor antagonist Drugs 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000003418 antiprogestin Substances 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000002357 endometrial effect Effects 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 7
- 230000000708 anti-progestin effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 208000000509 infertility Diseases 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 7
- HZPAJUSRVJDTMT-UHFFFAOYSA-N (2-hydroxy-2-methylpropyl)azanium;chloride Chemical compound Cl.CC(C)(O)CN HZPAJUSRVJDTMT-UHFFFAOYSA-N 0.000 description 6
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000000583 progesterone congener Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 230000003637 steroidlike Effects 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 235000007715 potassium iodide Nutrition 0.000 description 5
- 229960004839 potassium iodide Drugs 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000006213 vaginal ring Substances 0.000 description 5
- 229940044953 vaginal ring Drugs 0.000 description 5
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 4
- LUANXJIOUGKVRZ-UWVGGRQHSA-N (2s,4s)-4-(3-chlorophenoxy)pyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@@H]1OC1=CC=CC(Cl)=C1 LUANXJIOUGKVRZ-UWVGGRQHSA-N 0.000 description 4
- RGFRGRZSMVXTLF-ONGXEEELSA-N (2s,4s)-4-[(3-fluorophenyl)methyl]pyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@@H]1CC1=CC=CC(F)=C1 RGFRGRZSMVXTLF-ONGXEEELSA-N 0.000 description 4
- XKWDZEJCUWTBOM-BDAKNGLRSA-N (3s,5r)-3-amino-5-methylnonanoic acid Chemical compound CCCC[C@@H](C)C[C@H](N)CC(O)=O XKWDZEJCUWTBOM-BDAKNGLRSA-N 0.000 description 4
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000003886 aromatase inhibitor Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 229960002870 gabapentin Drugs 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- KKZMIDYKRKGJHG-UHFFFAOYSA-N methyl 4-cyanobenzoate Chemical compound COC(=O)C1=CC=C(C#N)C=C1 KKZMIDYKRKGJHG-UHFFFAOYSA-N 0.000 description 4
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 4
- 229960003248 mifepristone Drugs 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 4
- 229960001233 pregabalin Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000002379 progesterone receptor modulator Substances 0.000 description 4
- 102000017953 prostanoid receptors Human genes 0.000 description 4
- 108050007059 prostanoid receptors Proteins 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 description 3
- 108010037003 Buserelin Proteins 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 229940124638 COX inhibitor Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010069236 Goserelin Proteins 0.000 description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- 108010021717 Nafarelin Proteins 0.000 description 3
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 3
- 229960002184 abarelix Drugs 0.000 description 3
- 108010023617 abarelix Proteins 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 3
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 108700008462 cetrorelix Proteins 0.000 description 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 3
- 229960000766 danazol Drugs 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- JXEHXYFSIOYTAH-SFYZADRCSA-N imagabalin Chemical compound CCC[C@@H](C)C[C@H](N)CC(O)=O JXEHXYFSIOYTAH-SFYZADRCSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 210000004914 menses Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000002638 palliative care Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 201000007954 uterine fibroid Diseases 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- GWLVNOAPYJMHQV-BWZBUEFSSA-N (3r,4r,5r)-3-amino-4,5-dimethylheptanoic acid Chemical compound CC[C@@H](C)[C@@H](C)[C@H](N)CC(O)=O GWLVNOAPYJMHQV-BWZBUEFSSA-N 0.000 description 2
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 description 2
- KOWIZHDULJSRPT-WUKNDPDISA-N (3z)-3-[(4-bromophenyl)-(4-methylsulfonylphenyl)methylidene]oxolan-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C=1C=CC(Br)=CC=1)=C/1C(=O)OCC\1 KOWIZHDULJSRPT-WUKNDPDISA-N 0.000 description 2
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 2
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical compound CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- GCUBKZXHAKEOKP-UHFFFAOYSA-N 2-(3,3-difluorocyclobutyl)acetonitrile Chemical compound FC1(F)CC(CC#N)C1 GCUBKZXHAKEOKP-UHFFFAOYSA-N 0.000 description 2
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 2
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 2
- TZUNMYNSGZKAHU-UHFFFAOYSA-N 2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1N=CC=C1C(N)=O TZUNMYNSGZKAHU-UHFFFAOYSA-N 0.000 description 2
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 2
- MOEZPHHJIZLEKX-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclohexyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound N=1OC(=O)NC=1CC1(CN)CCCCC1 MOEZPHHJIZLEKX-UHFFFAOYSA-N 0.000 description 2
- TZJWSALUBPUGKT-UHFFFAOYSA-N 4-(4-cyclopropyl-5-iodo-1-propan-2-ylpyrazol-3-yl)benzonitrile Chemical compound IC=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 TZJWSALUBPUGKT-UHFFFAOYSA-N 0.000 description 2
- YGCJMSPOFJBXRA-UHFFFAOYSA-N 4-(4-ethyl-5-iodo-1-propan-2-ylpyrazol-3-yl)benzonitrile Chemical compound CCC1=C(I)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 YGCJMSPOFJBXRA-UHFFFAOYSA-N 0.000 description 2
- MQNJNYWHSCXMEE-UHFFFAOYSA-N 4-(5-amino-4-cyclopropyl-1-propan-2-ylpyrazol-3-yl)benzonitrile Chemical compound NC=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 MQNJNYWHSCXMEE-UHFFFAOYSA-N 0.000 description 2
- ZLLBZXOYDXZIBB-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-n-(cyclopropylmethyl)-4-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1N=C(C=2C=C(C)C(C#N)=CC=2)C(C)=C1C(=O)NCC1CC1 ZLLBZXOYDXZIBB-UHFFFAOYSA-N 0.000 description 2
- PKFNKSOGAYRRHI-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclobutyl-4-methylpyrazole-3-carboxylic acid Chemical compound OC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 PKFNKSOGAYRRHI-UHFFFAOYSA-N 0.000 description 2
- SIVWFSCCEFCZGK-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclopropyl-4-methyl-n-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 SIVWFSCCEFCZGK-UHFFFAOYSA-N 0.000 description 2
- FBYQOMWMZAJYSY-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclopropyl-n-(2-hydroxy-2-methylpropyl)-4-methylpyrazole-3-carboxamide Chemical compound CC(O)(C)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 FBYQOMWMZAJYSY-UHFFFAOYSA-N 0.000 description 2
- PJJNMUOCNGZKPJ-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound OC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 PJJNMUOCNGZKPJ-UHFFFAOYSA-N 0.000 description 2
- DYTPNQVJXMKNGA-GOSISDBHSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[[(2r)-oxolan-2-yl]methyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C([C@@H]1OCCC1)NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 DYTPNQVJXMKNGA-GOSISDBHSA-N 0.000 description 2
- DYTPNQVJXMKNGA-SFHVURJKSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[[(2s)-oxolan-2-yl]methyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C([C@H]1OCCC1)NC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 DYTPNQVJXMKNGA-SFHVURJKSA-N 0.000 description 2
- IEAYDBOPDLXDKO-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-ethyl-n-[2-(methylamino)-2-oxoethyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NCC(=O)NC)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 IEAYDBOPDLXDKO-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 229940121866 Beta hydroxysteroid dehydrogenase inhibitor Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 2
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
- 229940127462 Estrogen Synthesis Inhibitors Drugs 0.000 description 2
- 229940122880 Estrogen receptor agonist Drugs 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 229940119336 Microtubule stabilizer Drugs 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 2
- 229960004892 acemetacin Drugs 0.000 description 2
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000003936 androgen receptor antagonist Substances 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 108010070670 antarelix Proteins 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229960002719 buserelin Drugs 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000006315 carbonylation Effects 0.000 description 2
- 238000005810 carbonylation reaction Methods 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 229960003230 cetrorelix Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 238000007333 cyanation reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 108700025485 deslorelin Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229960002679 fentiazac Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 108700032141 ganirelix Proteins 0.000 description 2
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 2
- 229960003794 ganirelix Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960004761 gestrinone Drugs 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- ILULYDJFTJKQAP-UHFFFAOYSA-N hydron;propan-2-ylhydrazine;chloride Chemical compound [Cl-].CC(C)N[NH3+] ILULYDJFTJKQAP-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000002535 lyotropic effect Effects 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 description 2
- 229960002333 nafarelin Drugs 0.000 description 2
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229950011093 onapristone Drugs 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229960004662 parecoxib Drugs 0.000 description 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000044 progesterone antagonist Substances 0.000 description 2
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 description 2
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960002004 valdecoxib Drugs 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000005186 women's health Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IOGISYQVOGVIEU-UHFFFAOYSA-N (-4-Hydroxy-2-pyrrolidone Natural products OC1CNC(=O)C1 IOGISYQVOGVIEU-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- KFTRXTSNTQSGNE-UHFFFAOYSA-N (1-methylpyrazol-4-yl)methanamine Chemical compound CN1C=C(CN)C=N1 KFTRXTSNTQSGNE-UHFFFAOYSA-N 0.000 description 1
- YHFYRVZIONNYSM-UHNVWZDZSA-N (1s,3r)-3-aminocyclopentan-1-ol Chemical compound N[C@@H]1CC[C@H](O)C1 YHFYRVZIONNYSM-UHNVWZDZSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- BHRZNVHARXXAHW-SCSAIBSYSA-N (2r)-butan-2-amine Chemical compound CC[C@@H](C)N BHRZNVHARXXAHW-SCSAIBSYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- UPZSZIAAAGYKKQ-XVKPBYJWSA-N (2s,4s)-4-[(2,3-difluorophenyl)methyl]pyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@@H]1CC1=CC=CC(F)=C1F UPZSZIAAAGYKKQ-XVKPBYJWSA-N 0.000 description 1
- YDCYESLFDOQQBS-KWQFWETISA-N (2s,4s)-4-[(3-fluorophenoxy)methyl]pyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@@H]1COC1=CC=CC(F)=C1 YDCYESLFDOQQBS-KWQFWETISA-N 0.000 description 1
- MDZKTVVUZBIKGI-UHFFFAOYSA-N (3,3-difluorocyclobutyl)methanol Chemical compound OCC1CC(F)(F)C1 MDZKTVVUZBIKGI-UHFFFAOYSA-N 0.000 description 1
- HLISOYNJVMWYQM-IWSPIJDZSA-N (3r,4r,5r)-3-amino-4,5-dimethyloctanoic acid Chemical compound CCC[C@@H](C)[C@@H](C)[C@H](N)CC(O)=O HLISOYNJVMWYQM-IWSPIJDZSA-N 0.000 description 1
- LMNUAUVWBCVMFS-ZDUSSCGKSA-N (3s)-3-[tert-butyl(dimethyl)silyl]oxy-n-(2,2-diethoxyethyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CCOC(OCC)CNC1=NC[C@@H](O[Si](C)(C)C(C)(C)C)C1 LMNUAUVWBCVMFS-ZDUSSCGKSA-N 0.000 description 1
- SIRQBZJUYVPMIC-SFYZADRCSA-N (3s,5r)-3-(aminomethyl)-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](CN)CC(O)=O SIRQBZJUYVPMIC-SFYZADRCSA-N 0.000 description 1
- KKXFMWXZXDUYBF-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCC[C@@H](C)C[C@H](CN)CC(O)=O KKXFMWXZXDUYBF-BDAKNGLRSA-N 0.000 description 1
- SSFYNNBUYYSXPA-PWSUYJOCSA-N (3s,5r)-3-(aminomethyl)-6-cyclopentyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CCCC1 SSFYNNBUYYSXPA-PWSUYJOCSA-N 0.000 description 1
- NOTGKXLKLLOOEU-SCZZXKLOSA-N (3s,5r)-3-(aminomethyl)-6-cyclopropyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CC1 NOTGKXLKLLOOEU-SCZZXKLOSA-N 0.000 description 1
- GUEQOLSQPOTTME-RQJHMYQMSA-N (3s,5r)-3-amino-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](N)CC(O)=O GUEQOLSQPOTTME-RQJHMYQMSA-N 0.000 description 1
- BWRYNNCGEDOTRW-GXDHUFHOSA-N (4e)-4-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-2-methyloxazinan-3-one Chemical compound O=C1N(C)OCC\C1=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 BWRYNNCGEDOTRW-GXDHUFHOSA-N 0.000 description 1
- BEVGOGJIDJYUNN-QMMMGPOBSA-N (4s)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidin-2-one Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]1CNC(=O)C1 BEVGOGJIDJYUNN-QMMMGPOBSA-N 0.000 description 1
- IOGISYQVOGVIEU-VKHMYHEASA-N (4s)-4-hydroxypyrrolidin-2-one Chemical compound O[C@@H]1CNC(=O)C1 IOGISYQVOGVIEU-VKHMYHEASA-N 0.000 description 1
- AKTXOQVMWSFEBQ-LCYFTJDESA-N (5z)-2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(\C=C/2C(N=C(N)S\2)=O)=C1 AKTXOQVMWSFEBQ-LCYFTJDESA-N 0.000 description 1
- QFSDEEQXHVJGNL-NUBCRITNSA-N (6r)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-6-amine;hydrochloride Chemical compound Cl.C1=CN2C[C@H](N)CC2=N1 QFSDEEQXHVJGNL-NUBCRITNSA-N 0.000 description 1
- OLXNUSXUUWAEGE-RXMQYKEDSA-N (6r)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-6-ol Chemical compound C1=CN2C[C@H](O)CC2=N1 OLXNUSXUUWAEGE-RXMQYKEDSA-N 0.000 description 1
- QFSDEEQXHVJGNL-JEDNCBNOSA-N (6s)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-6-amine;hydrochloride Chemical compound Cl.C1=CN2C[C@@H](N)CC2=N1 QFSDEEQXHVJGNL-JEDNCBNOSA-N 0.000 description 1
- OLXNUSXUUWAEGE-YFKPBYRVSA-N (6s)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-6-ol Chemical compound C1=CN2C[C@@H](O)CC2=N1 OLXNUSXUUWAEGE-YFKPBYRVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DPPHNCGGFCAZGX-UHFFFAOYSA-N 1,1-difluorocyclobutane Chemical compound FC1(F)CCC1 DPPHNCGGFCAZGX-UHFFFAOYSA-N 0.000 description 1
- OVKIDXBGVUQFFC-UHFFFAOYSA-N 1,1-dioxothiolan-3-amine Chemical compound NC1CCS(=O)(=O)C1 OVKIDXBGVUQFFC-UHFFFAOYSA-N 0.000 description 1
- OPCJOXGBLDJWRM-UHFFFAOYSA-N 1,2-diamino-2-methylpropane Chemical compound CC(C)(N)CN OPCJOXGBLDJWRM-UHFFFAOYSA-N 0.000 description 1
- JVTRZJXFAOQMRA-UHFFFAOYSA-N 1,3-oxazin-2-one Chemical class O=C1N=CC=CO1 JVTRZJXFAOQMRA-UHFFFAOYSA-N 0.000 description 1
- HJORCZCMNWLHMB-UHFFFAOYSA-N 1-(3-aminopropyl)pyrrolidin-2-one Chemical compound NCCCN1CCCC1=O HJORCZCMNWLHMB-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- LPPDMYXDYJNNON-UHFFFAOYSA-N 1-pyrrol-1-ylpropan-1-one Chemical compound CCC(=O)N1C=CC=C1 LPPDMYXDYJNNON-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 1
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- MYQXHLQMZLTSDB-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OC(CC)CC2=C1 MYQXHLQMZLTSDB-UHFFFAOYSA-N 0.000 description 1
- XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 description 1
- MQIMZDXIAHJKQP-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol Chemical compound N=1C2=CC(O)=CC(C=C)=C2OC=1C1=CC=C(O)C(F)=C1 MQIMZDXIAHJKQP-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical compound CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- WGDADRBTCPGSDG-UHFFFAOYSA-N 2-[[4,5-bis(4-chlorophenyl)-1,3-oxazol-2-yl]sulfanyl]propanoic acid Chemical compound O1C(SC(C)C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(Cl)C=C1 WGDADRBTCPGSDG-UHFFFAOYSA-N 0.000 description 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- QCQZFSUBYDWVBG-UHFFFAOYSA-N 2-amino-n-ethylacetamide Chemical compound CCNC(=O)CN QCQZFSUBYDWVBG-UHFFFAOYSA-N 0.000 description 1
- OTODJUJPEZDJAD-UHFFFAOYSA-N 2-butan-2-yl-5-(4-cyanophenyl)-4-ethyl-n-[2-(methylamino)-2-oxoethyl]pyrazole-3-carboxamide Chemical compound CCC1=C(C(=O)NCC(=O)NC)N(C(C)CC)N=C1C1=CC=C(C#N)C=C1 OTODJUJPEZDJAD-UHFFFAOYSA-N 0.000 description 1
- FAUQRRGKJKMEIW-UHFFFAOYSA-N 2-cyclopropylacetonitrile Chemical compound N#CCC1CC1 FAUQRRGKJKMEIW-UHFFFAOYSA-N 0.000 description 1
- BFPCWNJLKUBDAR-UHFFFAOYSA-N 2-cyclopropylethanamine;hydrochloride Chemical compound Cl.NCCC1CC1 BFPCWNJLKUBDAR-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical compound O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 description 1
- IGOPOYHPIKTQSS-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-amine;hydrochloride Chemical compound [Cl-].[NH3+]CCC(F)(F)F IGOPOYHPIKTQSS-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- NSSOSHDCWCMNDM-UHFFFAOYSA-N 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile Chemical compound C1=C(C#N)C2=CC(O)=CC=C2C=C1C1=CC=C(O)C(F)=C1 NSSOSHDCWCMNDM-UHFFFAOYSA-N 0.000 description 1
- DAKDZFHRPCZHMW-UHFFFAOYSA-N 3-(4-cyanophenyl)-5-iodo-1-propan-2-ylpyrazole-4-carbonitrile Chemical compound N#CC1=C(I)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 DAKDZFHRPCZHMW-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- SLSXJDWULCUWHJ-UHFFFAOYSA-N 4-(1-cyclobutyl-5-iodo-4-methylpyrazol-3-yl)benzonitrile Chemical compound CC1=C(I)N(C2CCC2)N=C1C1=CC=C(C#N)C=C1 SLSXJDWULCUWHJ-UHFFFAOYSA-N 0.000 description 1
- PURFEZVKTRYABP-UHFFFAOYSA-N 4-(1-cyclopropyl-5-iodo-4-methylpyrazol-3-yl)benzonitrile Chemical compound CC1=C(I)N(C2CC2)N=C1C1=CC=C(C#N)C=C1 PURFEZVKTRYABP-UHFFFAOYSA-N 0.000 description 1
- SHZIAKFGGGSKRH-UHFFFAOYSA-N 4-(2-cyano-2-cyclopropylacetyl)-2-methylbenzonitrile Chemical compound C1=C(C#N)C(C)=CC(C(=O)C(C#N)C2CC2)=C1 SHZIAKFGGGSKRH-UHFFFAOYSA-N 0.000 description 1
- KJJRYVYEMFUEPE-UHFFFAOYSA-N 4-(2-cyano-3-phenylpropanoyl)benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(=O)C(C#N)CC1=CC=CC=C1 KJJRYVYEMFUEPE-UHFFFAOYSA-N 0.000 description 1
- HFABIHFBLNTOOW-UHFFFAOYSA-N 4-(2-cyanoacetyl)benzonitrile Chemical compound N#CCC(=O)C1=CC=C(C#N)C=C1 HFABIHFBLNTOOW-UHFFFAOYSA-N 0.000 description 1
- ABSVKTOLMIFOGB-UHFFFAOYSA-N 4-(2-cyanobutanoyl)benzonitrile Chemical compound CCC(C#N)C(=O)C1=CC=C(C#N)C=C1 ABSVKTOLMIFOGB-UHFFFAOYSA-N 0.000 description 1
- LHYWTMKETGOWNE-UHFFFAOYSA-N 4-(2-cyanopropanoyl)benzonitrile Chemical compound N#CC(C)C(=O)C1=CC=C(C#N)C=C1 LHYWTMKETGOWNE-UHFFFAOYSA-N 0.000 description 1
- KZFRRCZGTILJBM-UHFFFAOYSA-N 4-(4-benzyl-5-iodo-1-propan-2-ylpyrazol-3-yl)benzonitrile Chemical compound IC=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1CC1=CC=CC=C1 KZFRRCZGTILJBM-UHFFFAOYSA-N 0.000 description 1
- UCHMVDPMIKRGDI-UHFFFAOYSA-N 4-(4-benzyl-5-methyl-1-propan-2-ylpyrazol-3-yl)benzonitrile Chemical compound CC=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1CC1=CC=CC=C1 UCHMVDPMIKRGDI-UHFFFAOYSA-N 0.000 description 1
- MDCSSORWNCMBEV-UHFFFAOYSA-N 4-(4-cyclopropyl-5-iodo-1-propan-2-ylpyrazol-3-yl)-2-methylbenzonitrile Chemical compound IC=1N(C(C)C)N=C(C=2C=C(C)C(C#N)=CC=2)C=1C1CC1 MDCSSORWNCMBEV-UHFFFAOYSA-N 0.000 description 1
- JGVAIFHVLCBSEP-UHFFFAOYSA-N 4-(5-amino-1-cyclobutyl-4-methylpyrazol-3-yl)benzonitrile Chemical compound CC1=C(N)N(C2CCC2)N=C1C1=CC=C(C#N)C=C1 JGVAIFHVLCBSEP-UHFFFAOYSA-N 0.000 description 1
- VKBOGWBMWNPWCT-UHFFFAOYSA-N 4-(5-amino-1-propan-2-ylpyrazol-3-yl)benzonitrile Chemical compound C1=C(N)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 VKBOGWBMWNPWCT-UHFFFAOYSA-N 0.000 description 1
- ZUHAVFVBGKOXND-UHFFFAOYSA-N 4-(5-amino-4-cyclopropyl-1-propan-2-ylpyrazol-3-yl)-2-methylbenzonitrile Chemical compound NC=1N(C(C)C)N=C(C=2C=C(C)C(C#N)=CC=2)C=1C1CC1 ZUHAVFVBGKOXND-UHFFFAOYSA-N 0.000 description 1
- XMHUFQUBXAFQDK-UHFFFAOYSA-N 4-(5-amino-4-iodo-1-propan-2-ylpyrazol-3-yl)benzonitrile Chemical compound IC1=C(N)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 XMHUFQUBXAFQDK-UHFFFAOYSA-N 0.000 description 1
- KQOAJQAEAXJNOH-UHFFFAOYSA-N 4-(5-amino-4-methyl-1-propan-2-ylpyrazol-3-yl)-2-methylbenzonitrile Chemical compound CC1=C(N)N(C(C)C)N=C1C1=CC=C(C#N)C(C)=C1 KQOAJQAEAXJNOH-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- IHYUPLGHQKJENA-UHFFFAOYSA-N 4-Pyrimidine Methanamine (hydrochloride) Chemical compound Cl.NCC1=CC=NC=N1 IHYUPLGHQKJENA-UHFFFAOYSA-N 0.000 description 1
- WFLKKPIRPLLDII-UHFFFAOYSA-N 4-[2-cyano-2-(3,3-difluorocyclobutyl)acetyl]benzonitrile Chemical compound C1C(F)(F)CC1C(C#N)C(=O)C1=CC=C(C#N)C=C1 WFLKKPIRPLLDII-UHFFFAOYSA-N 0.000 description 1
- JYDKWLLGKRUMOT-UHFFFAOYSA-N 4-[4-(3,3-difluorocyclobutyl)-5-iodo-1-propan-2-ylpyrazol-3-yl]benzonitrile Chemical compound IC=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC(F)(F)C1 JYDKWLLGKRUMOT-UHFFFAOYSA-N 0.000 description 1
- DYTOFBOWTQIMFF-UHFFFAOYSA-N 4-[5-amino-4-(3,3-difluorocyclobutyl)-1-propan-2-ylpyrazol-3-yl]benzonitrile Chemical compound NC=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC(F)(F)C1 DYTOFBOWTQIMFF-UHFFFAOYSA-N 0.000 description 1
- NLPHXWGWBKZSJC-UHFFFAOYSA-N 4-acetylbenzonitrile Chemical compound CC(=O)C1=CC=C(C#N)C=C1 NLPHXWGWBKZSJC-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- JIJCAWBWXSQHLU-UHFFFAOYSA-N 4-benzyl-5-(4-cyanophenyl)-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound OC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1CC1=CC=CC=C1 JIJCAWBWXSQHLU-UHFFFAOYSA-N 0.000 description 1
- BQQLLWCNSFXHHF-UHFFFAOYSA-N 4-chloro-5-(4-cyanophenyl)-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound ClC1=C(C(O)=O)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 BQQLLWCNSFXHHF-UHFFFAOYSA-N 0.000 description 1
- SMYHMRBLFGYWAA-UHFFFAOYSA-N 4-cyano-5-(4-cyano-3-methylphenyl)-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound N#CC1=C(C(O)=O)N(C(C)C)N=C1C1=CC=C(C#N)C(C)=C1 SMYHMRBLFGYWAA-UHFFFAOYSA-N 0.000 description 1
- AZVFZCMTAVLJDW-UHFFFAOYSA-N 4-cyano-5-(4-cyanophenyl)-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound N#CC1=C(C(O)=O)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 AZVFZCMTAVLJDW-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- LRWMRSIKFDCNJJ-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound OC(=O)C=1N(C(C)C)N=C(C=2C=C(C)C(C#N)=CC=2)C=1C1CC1 LRWMRSIKFDCNJJ-UHFFFAOYSA-N 0.000 description 1
- VMKPGPMMQWXLJH-UHFFFAOYSA-N 5-(4-cyano-3-methylphenyl)-4-methyl-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound CC1=C(C(O)=O)N(C(C)C)N=C1C1=CC=C(C#N)C(C)=C1 VMKPGPMMQWXLJH-UHFFFAOYSA-N 0.000 description 1
- YVAATYQYZGXYHX-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclobutyl-4-methyl-n-[2-(methylamino)-2-oxoethyl]pyrazole-3-carboxamide Chemical compound CNC(=O)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 YVAATYQYZGXYHX-UHFFFAOYSA-N 0.000 description 1
- UWCYXOGMFRIUGH-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclobutyl-n,4-dimethylpyrazole-3-carboxamide Chemical compound CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 UWCYXOGMFRIUGH-UHFFFAOYSA-N 0.000 description 1
- TZPWEISEDROZNX-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclobutyl-n-(2-hydroxy-2-methylpropyl)-4-methylpyrazole-3-carboxamide Chemical compound CC(O)(C)CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 TZPWEISEDROZNX-UHFFFAOYSA-N 0.000 description 1
- YOQBZXHUZVMUNY-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclobutyl-n-(cyclopropylmethyl)-4-methylpyrazole-3-carboxamide Chemical compound C1CC1CNC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 YOQBZXHUZVMUNY-UHFFFAOYSA-N 0.000 description 1
- VLWAYOVLOXMWNO-UHFFFAOYSA-N 5-(4-cyanophenyl)-2-cyclopropyl-4-methylpyrazole-3-carboxylic acid Chemical compound OC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CC1 VLWAYOVLOXMWNO-UHFFFAOYSA-N 0.000 description 1
- QXHVKOTVLCIWHI-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-(3,3-difluorocyclobutyl)-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound OC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC(F)(F)C1 QXHVKOTVLCIWHI-UHFFFAOYSA-N 0.000 description 1
- BJRLXZSHCGSCEJ-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-(pyrimidin-4-ylmethyl)pyrazole-3-carboxamide Chemical compound C=1C=NC=NC=1CNC(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 BJRLXZSHCGSCEJ-UHFFFAOYSA-N 0.000 description 1
- IXGJGSHKEQXZDP-UNTBIKODSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-[(3r)-pyrrolidin-3-yl]pyrazole-3-carboxamide;hydrochloride Chemical compound Cl.N([C@H]1CNCC1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 IXGJGSHKEQXZDP-UNTBIKODSA-N 0.000 description 1
- IXGJGSHKEQXZDP-LMOVPXPDSA-N 5-(4-cyanophenyl)-4-cyclopropyl-2-propan-2-yl-n-[(3s)-pyrrolidin-3-yl]pyrazole-3-carboxamide;hydrochloride Chemical compound Cl.N([C@@H]1CNCC1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 IXGJGSHKEQXZDP-LMOVPXPDSA-N 0.000 description 1
- ZVQIRHXPNBGJEL-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-ethyl-2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound CC(C)N1C(C(O)=O)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 ZVQIRHXPNBGJEL-UHFFFAOYSA-N 0.000 description 1
- ABHXMAYIJUGROV-UHFFFAOYSA-N 5-(4-cyanophenyl)-4-ethyl-n-methyl-2-propan-2-ylpyrazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 ABHXMAYIJUGROV-UHFFFAOYSA-N 0.000 description 1
- ABXJTTPAABNOFP-UHFFFAOYSA-N 5-amino-1-methylpiperidin-2-one Chemical compound CN1CC(N)CCC1=O ABXJTTPAABNOFP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 229940124011 Androgen receptor agonist Drugs 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UDVMXBBSEPROLV-UHFFFAOYSA-N CC(C)C(N(CC1)CC1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O Chemical compound CC(C)C(N(CC1)CC1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O UDVMXBBSEPROLV-UHFFFAOYSA-N 0.000 description 1
- RSLGKBCEJSCKQG-UHFFFAOYSA-N CC(C)[n](c(C(NCC(NC)=O)=O)c1C)nc1-c(cc1C)ccc1C#N Chemical compound CC(C)[n](c(C(NCC(NC)=O)=O)c1C)nc1-c(cc1C)ccc1C#N RSLGKBCEJSCKQG-UHFFFAOYSA-N 0.000 description 1
- HITUFEDNQOCJHU-AWEZNQCLSA-N CC(C)[n](c(C(NC[C@H](C)O)=O)c1C#N)nc1-c(cc1C)ccc1C#C Chemical compound CC(C)[n](c(C(NC[C@H](C)O)=O)c1C#N)nc1-c(cc1C)ccc1C#C HITUFEDNQOCJHU-AWEZNQCLSA-N 0.000 description 1
- VGANKIYBENFTIV-NSHDSACASA-N CC(C)[n](c(C(NC[C@H](C)O)=O)c1Cl)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC[C@H](C)O)=O)c1Cl)nc1-c(cc1)ccc1C#N VGANKIYBENFTIV-NSHDSACASA-N 0.000 description 1
- NCGWQXXXQYNVEY-LBPRGKRZSA-N CC(C)[n](c(C(NC[C@H](C)O)=O)c1N)nc1-c(cc1C)ccc1C#N Chemical compound CC(C)[n](c(C(NC[C@H](C)O)=O)c1N)nc1-c(cc1C)ccc1C#N NCGWQXXXQYNVEY-LBPRGKRZSA-N 0.000 description 1
- LGBPFUWCXLEHMN-UHFFFAOYSA-N CC(C)[n](c(C(OC)=O)c1Cc2ccccc2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(OC)=O)c1Cc2ccccc2)nc1-c(cc1)ccc1C#N LGBPFUWCXLEHMN-UHFFFAOYSA-N 0.000 description 1
- BRNAJSVYMPUPNQ-UHFFFAOYSA-N CC(C)[n](c(N)c1C#N)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(N)c1C#N)nc1-c(cc1)ccc1C#N BRNAJSVYMPUPNQ-UHFFFAOYSA-N 0.000 description 1
- CYHPMFDSDVFSGP-UHFFFAOYSA-N CCC(C)[n](c(I)c1CC)nc1-c(cc1)ccc1C#N Chemical compound CCC(C)[n](c(I)c1CC)nc1-c(cc1)ccc1C#N CYHPMFDSDVFSGP-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KATKLVYMJQVJMR-UHFFFAOYSA-N Cc1c(C(O)=O)[n](C2COCC2)nc1-c(cc1)ccc1C#N Chemical compound Cc1c(C(O)=O)[n](C2COCC2)nc1-c(cc1)ccc1C#N KATKLVYMJQVJMR-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- HEAUOKZIVMZVQL-VWLOTQADSA-N Elagolix Chemical compound COC1=CC=CC(C=2C(N(C[C@H](NCCCC(O)=O)C=3C=CC=CC=3)C(=O)N(CC=3C(=CC=CC=3F)C(F)(F)F)C=2C)=O)=C1F HEAUOKZIVMZVQL-VWLOTQADSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- DIJUWBLZTLVHSX-CALCHBBNSA-N N([C@H]1C[C@@H](O)C1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 Chemical compound N([C@H]1C[C@@H](O)C1)C(=O)C=1N(C(C)C)N=C(C=2C=CC(=CC=2)C#N)C=1C1CC1 DIJUWBLZTLVHSX-CALCHBBNSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- HHJQOCYHSGBQAW-UHFFFAOYSA-N N=CC(C(C1)CC1(F)F)C(c(cc1)ccc1C#N)=O Chemical compound N=CC(C(C1)CC1(F)F)C(c(cc1)ccc1C#N)=O HHJQOCYHSGBQAW-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000034424 Painful defaecation Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 206010064050 Polymenorrhagia Diseases 0.000 description 1
- 206010036086 Polymenorrhoea Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- YNOGYQAEJGADFJ-RXMQYKEDSA-N [(2r)-oxolan-2-yl]methanamine Chemical compound NC[C@H]1CCCO1 YNOGYQAEJGADFJ-RXMQYKEDSA-N 0.000 description 1
- YNOGYQAEJGADFJ-YFKPBYRVSA-N [(2s)-oxolan-2-yl]methanamine Chemical compound NC[C@@H]1CCCO1 YNOGYQAEJGADFJ-YFKPBYRVSA-N 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229950003620 asoprisnil Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004190 broad ligament Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229950005608 bucloxic acid Drugs 0.000 description 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940112106 cetrotide Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229950010886 clidanac Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
- AQOZZSWECZTDNR-UHFFFAOYSA-N cyclobutylhydrazine;hydrochloride Chemical compound Cl.NNC1CCC1 AQOZZSWECZTDNR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SDYFTMROHZCYSK-UHFFFAOYSA-N cyclopropylhydrazine;hydrochloride Chemical compound Cl.NNC1CC1 SDYFTMROHZCYSK-UHFFFAOYSA-N 0.000 description 1
- 229950000393 darbufelone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CIYGMWIAXRMHQS-UHFFFAOYSA-N ditert-butyl oxalate Chemical compound CC(C)(C)OC(=O)C(=O)OC(C)(C)C CIYGMWIAXRMHQS-UHFFFAOYSA-N 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229950004823 elagolix Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BXBRFSMPBOTZHJ-UHFFFAOYSA-N ethyl 3-oxocyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CC(=O)C1 BXBRFSMPBOTZHJ-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- 229950005722 flosulide Drugs 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229950007979 flufenisal Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950010931 furofenac Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- NVWZNEDLYYLQJC-UHFFFAOYSA-N methyl 2-amino-2-methylpropanoate;hydrochloride Chemical compound Cl.COC(=O)C(C)(C)N NVWZNEDLYYLQJC-UHFFFAOYSA-N 0.000 description 1
- GTZTYNPAPQKIIR-UHFFFAOYSA-N methyl 4-bromo-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C(C)=C1 GTZTYNPAPQKIIR-UHFFFAOYSA-N 0.000 description 1
- LIXWSMOADOOTOR-UHFFFAOYSA-N methyl 4-cyano-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(C#N)C(C)=C1 LIXWSMOADOOTOR-UHFFFAOYSA-N 0.000 description 1
- RAYOIMVTIBRGSE-UHFFFAOYSA-N methyl 4-cyano-5-(4-cyanophenyl)-2-propan-2-ylpyrazole-3-carboxylate Chemical compound CC(C)N1C(C(=O)OC)=C(C#N)C(C=2C=CC(=CC=2)C#N)=N1 RAYOIMVTIBRGSE-UHFFFAOYSA-N 0.000 description 1
- LUISIBAUCKXIAR-UHFFFAOYSA-N methyl 5-(4-cyano-3-methylphenyl)-4-cyclopropyl-2-propan-2-ylpyrazole-3-carboxylate Chemical compound C=1C=C(C#N)C(C)=CC=1C1=NN(C(C)C)C(C(=O)OC)=C1C1CC1 LUISIBAUCKXIAR-UHFFFAOYSA-N 0.000 description 1
- RGDNMZSUCZOCPT-UHFFFAOYSA-N methyl 5-(4-cyano-3-methylphenyl)-4-methyl-2-propan-2-ylpyrazole-3-carboxylate Chemical compound CC(C)N1C(C(=O)OC)=C(C)C(C=2C=C(C)C(C#N)=CC=2)=N1 RGDNMZSUCZOCPT-UHFFFAOYSA-N 0.000 description 1
- YXONIYQRYHXPQD-UHFFFAOYSA-N methyl 5-(4-cyanophenyl)-2-cyclobutyl-4-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=C(C)C(C=2C=CC(=CC=2)C#N)=NN1C1CCC1 YXONIYQRYHXPQD-UHFFFAOYSA-N 0.000 description 1
- YFBFIKMVBUNSEY-UHFFFAOYSA-N methyl 5-(4-cyanophenyl)-4-(3,3-difluorocyclobutyl)-2-propan-2-ylpyrazole-3-carboxylate Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)OC)=C1C1CC(F)(F)C1 YFBFIKMVBUNSEY-UHFFFAOYSA-N 0.000 description 1
- FKLKEQXJPMTOFB-UHFFFAOYSA-N methyl 5-(4-cyanophenyl)-4-ethyl-2-propan-2-ylpyrazole-3-carboxylate Chemical compound CC(C)N1C(C(=O)OC)=C(CC)C(C=2C=CC(=CC=2)C#N)=N1 FKLKEQXJPMTOFB-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- BOZILQFLQYBIIY-INTXDZFKSA-N mevinic acid Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)CCC=C21 BOZILQFLQYBIIY-INTXDZFKSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229950006616 miroprofen Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- JLPJFSCQKHRSQR-UHFFFAOYSA-N oxolan-3-one Chemical compound O=C1CCOC1 JLPJFSCQKHRSQR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 108010011957 ozarelix Proteins 0.000 description 1
- 229950008505 ozarelix Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 229960000825 proglumetacin Drugs 0.000 description 1
- PTXGHCGBYMQQIG-UHFFFAOYSA-N proglumetacin Chemical compound C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CCC(=O)OCCCN(CC1)CCN1CCOC(=O)CC(C1=CC(OC)=CC=C11)=C(C)N1C(=O)C1=CC=C(Cl)C=C1 PTXGHCGBYMQQIG-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- VIXWGKYSYIBATJ-UHFFFAOYSA-N pyrrol-2-one Chemical compound O=C1C=CC=N1 VIXWGKYSYIBATJ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004363 pyrrolin-3-yl group Chemical group [H]C1=NC([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 210000001659 round ligament Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 229940036197 supprelin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940086546 synarel Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- CMIBWIAICVBURI-SSDOTTSWSA-N tert-butyl (3r)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](N)C1 CMIBWIAICVBURI-SSDOTTSWSA-N 0.000 description 1
- CMIBWIAICVBURI-ZETCQYMHSA-N tert-butyl (3s)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](N)C1 CMIBWIAICVBURI-ZETCQYMHSA-N 0.000 description 1
- AAKGDLNWNKVEAY-WQLSENKSSA-N tert-butyl (z)-4-(4-cyanophenyl)-4-hydroxy-2-oxobut-3-enoate Chemical compound CC(C)(C)OC(=O)C(=O)\C=C(/O)C1=CC=C(C#N)C=C1 AAKGDLNWNKVEAY-WQLSENKSSA-N 0.000 description 1
- WWCYMVKFHWCWQZ-UHFFFAOYSA-N tert-butyl 3-(4-cyanophenyl)-1h-pyrazole-5-carboxylate Chemical compound N1C(C(=O)OC(C)(C)C)=CC(C=2C=CC(=CC=2)C#N)=N1 WWCYMVKFHWCWQZ-UHFFFAOYSA-N 0.000 description 1
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 1
- FSOZMSNFZLKMOX-UHFFFAOYSA-N tert-butyl 4-chloro-5-(4-cyanophenyl)-2-propan-2-ylpyrazole-3-carboxylate Chemical compound ClC1=C(C(=O)OC(C)(C)C)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 FSOZMSNFZLKMOX-UHFFFAOYSA-N 0.000 description 1
- MCBIEMCZBVVRBT-UHFFFAOYSA-N tert-butyl 5-(4-cyanophenyl)-2-propan-2-ylpyrazole-3-carboxylate Chemical compound C1=C(C(=O)OC(C)(C)C)N(C(C)C)N=C1C1=CC=C(C#N)C=C1 MCBIEMCZBVVRBT-UHFFFAOYSA-N 0.000 description 1
- WSUMHFNEPOYLJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxycyclobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CC(O)C1 WSUMHFNEPOYLJM-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- SIUPISOJEQUFLR-JTQLQIEISA-N tert-butyl-[[(3s)-5-ethoxy-3,4-dihydro-2h-pyrrol-3-yl]oxy]-dimethylsilane Chemical compound CCOC1=NC[C@@H](O[Si](C)(C)C(C)(C)C)C1 SIUPISOJEQUFLR-JTQLQIEISA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229950011372 teverelix Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- 229950006150 tioxaprofen Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000011539 total abdominal hysterectomy Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 description 1
- 229950008546 trimegestone Drugs 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- This invention relates to novel amide compounds and their derivatives, which are useful in therapy, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. It also relates to compositions containing such compounds and their uses, for example their use in medicine.
- a preferred use of the compounds is in the treatment of conditions alleviated by use of a progesterone receptor modulator, preferably a progesterone receptor antagonist.
- the compounds are useful in contraception, the treatment of endometriosis, uterine fibroids and related conditions, and in the treatment of breast, ovarian or endometrial cancer.
- Endometriosis is a common gynaecological disease that affects 10-20% women of reproductive age and manifests itself in the presence of functional ectopic endometrial glands and stroma at locations outside the uterine cavity
- the Sampson theory proposes that the development of endometriosis is a consequence of retrograde dissemination and implantation of endometrial tissue into the peritoneal cavity during menstruation. Following attachment, the fragments of endometrium recruit a vascular supply and undergo cycles of proliferation and shedding under local and systemic hormonal controls. In women with patent fallopian tubes, retrograde menstruation appears to be a universal phenomenon ⁇ Liu, D. T. (Hitchcock, A.). British Journal of Obstetrics & Gynaecology 93, 859- 862. ⁇ .
- the disease often manifests itself as rectovaginal endometriosis or adenomyosis, ovarian cystic endometriomas and, most commonly, peritoneal endometriosis.
- the major sites of attachment and lesion growth within the pelvis are the ovaries, broad and round ligaments, fallopian tubes, cervix, vag ina, peritoneum and the pouch of Douglas .
- endometriosis can cause profound structural modification to the peritoneal cavity, including multi-organ adhesions and fibrosis.
- Symptomatic endometriosis can be managed medically and surgically, where the intention is to remove the ectopic lesion tissue.
- Surgical intervention can be either conservative, aiming to preserve the reproductive potential of the patient, or comparatively radical for severe disease, involving dissection of the urinary tract, bowel, and rectovaginal septum, or total abdominal hysterectomy and bilateral salpingo-oopherectomy.
- Medical pharmacological treatments such as the androgenic therapies, danazol and gestrinone, the constellation of GnRH agonists, buserelin, goserelin, leuprolide, nafarelin and triptorelin, GnRH antagonists, cetrorelix and abarelix, as well as the progestogens, including medroxyprogesterone acetate, induce lesion atrophy by suppressing the production of estrogen.
- These approaches are not without unwanted side effects; for danazol and gestrinone these include weight gain, hirsuitism, acne, mood changes and metabolic effects on the cardiovascular system.
- the group of GnRH agonists and antagonists are found to cause a profound suppression of estrogen leading to vasomotor effects (hot flashes) and depletion of bone mineral density, which restricts their use to only six months of therapy.
- the group of progestogens including medroxyprogesterone acetate, suppress the gonadotropins, but do not down-regulate ovarian estrogen production to the same extent as the GnRH analogues.
- the side effects include irregular bleeding, bloating, weight gain and metabolic effects on the cardiovascular system.
- Steroidal progestins are commonly used in women's health, such as in contraception and hormone therapy and for the treatment of gynecological disorders.
- progesterone receptor antagonists may have potential applications in contraception and for the treatment of reproductive disorders such as fibroids and endometriosis as well as dysfunctional uterine bleeding and breast and ovarian carcinomas ⁇ Spitz, I. M. (2007), Expert Review of Obstetrics and Gynecology 2(2), 227-242 ⁇ .
- progesterone receptor agonists and antagonists are steroidal compounds.
- Progesterone receptor antagonists [anti-progestins (APs)], including the founding members of the class mifepristone (RU-486; Roussel UCLAF, Romainville, France), onapristone (ZK 98 299; Schering AG), ZK 137 316 and ZK-230 211 , are compounds that bind to the progesterone receptor (PR) and prevent progesterone-induced gene expression ⁇ Spitz, I. M. (2003). Steroids 68, 981-993. ⁇ .
- APs anti-progestins
- progesterone plays an essential role in the differentiation and ductal morphogenesis of endometrial tissue, but also participates in the inhibition of myometrial contractility and the polarisation of leukocyte Th1 /Th2 responses that are critical for embryo implantation and the maintenance of pregnancy.
- a number of studies have investigated the potential beneficial effects of anti-progestins on the signs and symptoms of endometriosis ⁇ Grow, D. R., et al. (1996). Journal of Clinical Endocrinology & Metabolism 81, 1933-1939.; Kettel, L. M., et al. (1996). Fertility & Sterility 65, 23-28.; Kettel, L.
- a further class of steroidal and non-steroidal compounds termed the progesterone receptor modulators (PRMs, or mesoprogestins), including asop r i s n i l ( J 867 , b e n z a l d e h y d e , 4-[(11 ⁇ , 17 ⁇ )-17-methoxy-17- (methoxymethyl)-3-oxoestra-4,9-dien-11 -yl]-, 1 -oxime; Jenpharm, TAP), J912, J956, J1042, have also been described.
- PRMs progesterone receptor modulators
- Asoprisnil and structurally-related PRMs differ from anti-progestins and progestins in animal models, demonstrating partial progestogenic activity in the rabbit endometrium (McPhail's test ⁇ McPhail, M. K. (1934). Journal of physiology 83, 145-156. ⁇ ) and guinea pig vagina, for instance.
- Pre-clinical studies with asoprisinil in primates have indicated that PRMs suppress endometrial growth and, unlike the effects of progestins, endometrial ER and PR expression is not repressed ⁇ Chwalisz, K., et al. (2000).
- PR-B The expression of both PR isoforms in reproductive tissues is altered during carcinogenesis.
- the over expression of PR-B has been shown to correlate with more aggressive endometrial and ovarian cancers ⁇ Fujimoto et al (1995) Tumour Biology 16, 254-60 ⁇ .
- a selective progesterone receptor antagonist wh ich is devoid of anti- glucocorticoid activity, may be less affected by dose-limiting side effects and prove effective in treating endometrial, ovarian and breast cancer.
- the compounds of the present invention have been found to have potentially useful pharmaceutical properties. They may be used to treat conditions such as endometriosis, uterine fibroids (leiomyomata) and menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareun ia, dyschexia and chron ic pelvic pain), chron ic pelvic pain syndrome, precocious puberty, cervical ripening, contraception (emergency), breast carcinoma, ovarian carcinoma, endometrial carcinoma, prostate carcinoma, pulmonary carcinoma, testicular carcinoma, gastric carcinoma, meningioma, anxiety, premenstrual syndrome, premenstrual dysphoric disorder, alcohol abuse and reward , or Charcot-Mahe-Tooth disease.
- Particularly of interest is the treatment of the following diseases or disorders: endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome, and breast, ovarian or endometrial cancer. More particularly of interest is the treatment or prevention of one or more pain and/or other symptoms associated with endometriosis and/or uterine fibroids.
- These symptoms may comprise dysmenorrhoea; chronic non-menstrual pelvic pain; dyspareunia; dyschexia; menorrhagia; lower abdominal or back pain; infertility and subfertility; dysuria; bloating and pain on micturition; nausea, vomiting and/or diarrohea.
- Such treatment may involve curative, prophylactic or palliative treatment of the underlying condition or of one or more symptoms of the condition, for example, pain.
- the compounds and derivatives of the present invention exhibit activity as progesterone receptor modulators and may be useful for treatment where progesterone receptor modulation is indicated.
- the compounds and derivatives of the present invention may be useful for treating endometriosis and/or uterine fibroids (leiomyomata), including the pain symptoms thereof, and and for the treatment of breast, ovarian or endometrial cancer.
- R 1 and R 2 each independently represent H, halogen, CF 3 , Ci -3 alkyl or Ci -3 alkoxy;
- R 3 represents Ci -6 alkyl, C 3- 6 cycloalkyl, phenyl (optionally substituted by one or more substituents each independently selected from R a ) or Het (optionally substituted by one or more substituents each independently selected from OH, oxo, or Ci -4 alkyl);
- R a represents halogen, CF 3 , or CN;
- Het represents a 5- or 6- membered, saturated, partially saturated, or aromatic, heterocyclic ring comprising (a) from 1 to 4 nitrogen atoms, or (b) 1 or 2 nitrogen atoms and 1 oxygen atom or 1 sulphur atom, or (c) 1 oxygen atom or 1 sulphur atom;
- R 4 represents H or Ci -3 alkyl;
- R 5 represents Ci -6 alkyl (optionally substituted by one or more substituents each independently selected from R b ), C 3-6 cycloalkyl (optionally substituted by one or more substituents each independently selected from oxo or OH), or Het 2 (optionally substituted by one or more substituents each independently selected from R d );
- R b represents OH, halogen, C 3-6 cycloalkyl, OCi -4 alkyl, COR C , NR d 2 , or Het 1 ;
- R c independently represents -NH 2 , -NHCi -4 alkyl, -N(Ci -4 alkyl) 2 , -OCi -4 alkyl or -Ci -4 alkyl;
- R d independently represents H or Ci -4 alkyl;
- Het 1 independently represents a 5- or 6- membered, saturated, partially saturated, or aromatic, heterocyclic ring comprising (a) from 1 to 4 nitrogen atoms, or (b) 1 or 2 nitrogen atoms and 1 oxygen atom or 1 sulphur atom, or (c) 1 oxygen atom or 1 sulphur atom, (optionally substituted by one or more substituents each independently selected from OH, oxo or Ci -4 alkyl);
- Het 2 represents a 4- to 6- membered, saturated, partially saturated, or aromatic, monocyclic heterocyclic ring, or a 7- to 12- membered saturated, partially saturated, or aromatic, bicyclic heterocyclic ring, comprising (a) from 1 to 4 nitrogen atoms, or (b) 1 or 2 nitrogen atoms and 1 oxygen atom or 1 sulphur atom, or (c) 1 oxygen atom or 1 sulphur atom; and
- R d represents Ci -4 alkyl, oxo, OH, COCi -4 alkyl, COOCi -4 alkyl, SO 2 Ci -4 alkyl, NH 2 , CONHCi -4 alkyl, or CON(Ci -4 alkyl) 2 ; and R 6 represents Ci -3 alkyl (optionally substituted by one or more substituents each independently selected from R f ), C 3-5 cycloalkyl (optionally substituted by one or more halogen), CN or halogen; where
- R f represents halogen or phenyl.
- compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt or solvate (including hydrate) thereof, and a pharmaceutically acceptable carrier.
- 6- membered saturated, partially saturated, or aromatic, heterocyclic ring comprising (a) from 1 to 4 nitrogen atoms, or (b) 1 or 2 nitrogen atoms and 1 oxygen atom, or (c) 1 oxygen atom,
- 6- membered saturated, partially saturated, or aromatic, heterocyclic ring comprising (a) from 1 to 2 nitrogen atoms, or (b) 1 or 2 nitrogen atoms and 1 oxygen atom, or (c) 1 oxygen atom,
- (xli) a compound of Formula (I), as defined above, or any of the embodiments (i) to (xl) above, wherein Het 2 represents a 4- to 6- membered saturated, partially saturated, or aromatic, monocyclic heterocyclic ring or a 7- to 12- membered saturated, partially saturated, or aromatic, bicyclic heterocyclic ring, comprising (a) from 1 to 4 nitrogen atoms, or (b) 1 or 2 nitrogen atoms and 1 oxygen atom, or (c) 1 oxygen atom, (optionally substituted with one or more substituents independently selected from oxo);
- (xlii) a compound of Formula (I), as defined above, or any of the embodiments (i) to (xli) above, wherein Het 2 represents a 4- to 6- membered saturated, partially saturated, or aromatic, monocyclic heterocyclic ring or a 7- to 12- membered saturated, partially saturated, or aromatic, bicyclic heterocyclic ring, comprising (a) 1 or 2 nitrogen atoms, or (b) 1 nitrogen atom and 1 oxygen atom, or (c) 1 oxygen atom, (optionally substituted with one or more substituents independently selected from oxo); (xliii) a compound of Formula (I), as defined above, or any of the embodiments (i) to (xlii) above, wherein Het 2 represents pyrrolidine, pyrrolidinone, pipehdinone, azetidine, tetrahydrofuran, dihydrofuranone; tetrahydropyran, or dihydropyrroloimidazole;
- (xlvi) a compound of Formula (I), as defined above, or any of the embodiments (i) to (xlv) above, wherein R 6 represents Ci-2 alkyl (optionally substituted by one or more phenyl substituents), C 3-4 cycloalkyl (optionally substituted by one or more F), CN or halogen, preferably methyl, ethyl, cyclopropyl, 3,3-difluorocyclobutyl, benzyl, cyano or chloro; (xlvii) a compound of Formula (I), as defined above, or any of the embodiments (i) to (xlvi) above, wherein R 6 represents Ci-3 alkyl, C3- 5 cycloalkyl, CN or halogen;
- (xlix) a compound of Formula (I), as defined above, or any of the embodiments (i) to (xlvi) above, wherein R 6 represents methyl, ethyl, cyclopropyl, 3,3-difluorocyclobutyl, chloro or cyano; (1) a compound of Formula (I), as defined above, or any of the embodiments (i) to (xlvi) above, wherein when R 6 represents cyclopropyl or methyl, preferably cyclopropyl.
- R 5 represents C-1-6 alkyl optionally substituted by hydroxy, fluoro, methoxy, Ci -4 alkanoyl, Ci -4 alkylaminocarbonyl, amino, Ci -4 alkoxycarbonyl, C3-6 cycloalkyl or Het 1 ; Het 2 , or C3-6 cycloalkyl optionally substituted by hydroxy; and preferably is Ci-6 alkyl optionally substituted by hydroxy;
- (lii) a compound of Formula (I), as defined above, or any of the embodiments (i) to (Ii) above, as permissible, wherein R 5 represents methyl, ethyl, n-propyl, isopropyl, t-butyl, 2-butyl, 2,2-dimethylprop- 1 -yl, 2-methyl-2-hydroxyprop-1 -yl, 2-hydroxyprop-1-yl, 3-hydroxy-2- methylprop-2-yl, 2,2,2-trifluoroethyl, 3-methoxyprop-1-yl, 2- methoxyethyl, 3,3,3-thfluoroprop-1-yl, acetyl methyl, methylaminocarbonylmethyl, ethylaminocarbonylmethyl, 2- aminoethyl, 2-amino-2-methylprop-1-yl , 2-methoxycarbonylprop-2- yl, cyclopropyl methyl, 2-cyclopropylethyl, te
- R 1 , R 2 and R 5 are as defined for a compound of formula (I) above and preferably R 1 and R 2 are both H.
- R 3 and R 5 are as defined for a compound of formula (I) above.
- R 5 and R 6 are as defined for a compound of formula (I) above.
- Particular compounds of interest falling within the scope of the invention are: 3-(4-cyanophenyl)-4-cyclopropyl-N-(2-hydroxy-2-methylpropyl)-1-isopropyl- 1 H-pyrazole-5-carboxamide; 3-(4-cyanophenyl)-4-cyclopropyl-N-[(2S)-2-hydroxypropyl]-1-isopropyl-1 H- pyrazole-5-carboxamide;
- alkyl groups containing the requisite number of carbon atoms can be unbranched or branched chain .
- Examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl.
- alkyloxy alkoxy
- alkyloxy alkoxy
- cycloalkyl examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- halogen means fluoro, chloro, bromo or iodo.
- Pharmaceutically acceptable derivatives of the compounds of formula (I) included in the present invention include salts, solvates (including hydrates), complexes, polymorphs and crystal habits thereof, prodrugs, stereoisomers, geometric isomers, tautomeric forms, and isotopic variations of compounds of formula (I).
- pharmaceutically acceptable derivatives of compounds of formula (I) comprise salts or solvates (including hydrates) of the compounds of formula (I).
- the pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts thereof.
- Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochlohde/chlohde, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, sacchar
- base salts are formed from bases that form non-toxic salts.
- bases include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
- Hemi-salts of acids and bases may also be formed, for example, hemi- sulphate and hemicalcium salts.
- compositions of formula (I) may be prepared by one or more of three methods: (i) by reacting the compound of formula (I) with the desired acid or base; (ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (I) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or (iii) by converting one salt of the compound of formula (I) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.
- salts of prodrugs of compounds of formula (I) can be prepared in an analogous manner.
- the compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline.
- the term 'amorphous' refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid.
- a change from solid to liquid properties occurs which is characterised by a change of state, typically second order ('glass transition').
- 'crystalline' refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order ('melting point').
- the compounds and salts of the invention may also exist in unsolvated and solvated forms.
- the term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- the term 'hydrate' is employed when said solvent is water.
- Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules.
- channel hydrates the water molecules lie in lattice channels where they are next to other water molecules.
- metal-ion coordinated hydrates the water molecules are bonded to the metal ion.
- the complex When the solvent or water is tightly bound, the complex will have a well- defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bou nd , as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
- multi-component complexes other than salts and solvates
- complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals.
- the latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt.
- Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together - see Chem Commun, X7_, 1889-1896, by O. Almarsson and M. J. Zaworotko (2004).
- the compounds of the invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions.
- the mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution).
- Mesomorphism arising as the result of a change in temperature is described as 'thermotropic' and that resulting from the addition of a second component, such as water or another solvent, is described as 'lyotropic'.
- references to compounds of formula (I) include references to salts, solvates, multi-component complexes, prodrugs, liquid crystals, etc. thereof and to solvates, multi-component complexes and liquid crystals of salts thereof, etc.
- 'prodrugs' of the compounds of formula (I) are also within the scope of the invention.
- certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves, can be converted into compounds of formula (I) having the desired activity, for example by hydrolytic cleavage, when administered into, or onto, the body.
- Such derivatives are referred to as 'prodrugs'.
- Further information on the use of prodrugs may be found in "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and "Bioreversible Carriers in Drug Design", Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association).
- Prodrugs in accordance with the invention can be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985).
- prodrugs in accordance with the invention include
- the compound of formula (I) contains an alcohol functionality, the phosphate ester thereof, for example, a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by PO 3 H 2 (these prodrugs may be prepared by the methods laid out in WO 99/33815) and (ii) where the compound of formula (I) contains a primary or secondary amino functionality (-NH 2 Or -NHR where R ⁇ H), an amide thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of formula (I) is/are replaced by (Ci-Cio)alkanoyl.
- metabolites of compounds of formula (I) that is, compounds formed in vivo upon administration of the drug.
- the metabolites of the compounds of formula (I) when formed in vivo.
- Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
- the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) or derivative contains an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid.
- a suitable optically active compound for example, an alcohol, or, in the case where the compound of formula (I) or derivative contains an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid.
- the resulting diastereomehc mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
- Chiral compounds of the invention may be obtained in enantiomerically-enriched form using chromatography, typically H PLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture.
- chromatography typically H PLC
- a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1 % diethylamine.
- the first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts.
- the second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
- Racemic mixtures may be separated by conventional techniques known to those ski l l ed i n the art - see, for example, "Stereochemistry of Organic Compounds" by E. L. ENeI and S. H. Wilen (Wiley, 1994).
- the present invention includes all pharmaceutically acceptable isotopically- labelled compounds of formula (I) or derivatives herein defined, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
- isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 CI, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
- isotopically-labelled compounds of formula (I) or derivative herein defined are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labelled compounds of formula (I) or derivatives herein defined can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.
- solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, de-acetone, d 6 -DMSO.
- the compounds of formula (I) or their derivatives herein defined should be assessed for their biopharmaceutical properties, such as solubility and solution stability (across pH), permeability, etc., in order to select the most appropriate dosage form and route of administration for treatment of the proposed indication.
- Compounds (I) and derivatives herein defined of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
- the compounds (I) and derivatives of the invention may be administered alone or in combination with one or more other compounds or derivatives of the invention or in combination with one or more other therapeutically active substances (drugs) (or as any combination thereof).
- the compounds (I) and derivatives of the present invention may be administered in combination with COX inhibitors.
- a pharmaceutical product containing a progesterone receptor modulator and one or more COX inh ibitors as a combined preparation for simultaneous, separate or sequential use in the treatment of endometriosis.
- COX inhibitors useful for combining with the compounds of formula (I) and derivatives thereof of the present invention include, but are not limited to:
- meloxicam (CAS registry number 71125-38-7; described in U.S. Patent No. 4,233,299), or a pharmaceutically acceptable salt or prodrug thereof;
- Parecoxib (described in U.S. Patent No. 5,932,598), which is a therapeutically effective prodrug of the tricyclic Cox-2 selective inhibitor valdecoxib (described in U.S. Patent No. 5,633,272), in particular sodium parecoxib;
- ABT-963 (described in International Patent Application Publication No.
- Nimesulide (described in U.S. Patent No. 3,840,597), flosulide (discussed in J. Carter, Exp.Qpin.Ther.Patents, 8(1 ), 21-29 (1997)), NS- 398 (disclosed in U.S. Patent No. 4,885,367), SD 8381 (described in U.S. Patent No. 6,034,256), BMS-347070 (described in U.S. Patent No.
- the compounds of formula (I) or derivatives as herein defined of the present invention may be administered in combination with an agent which lowers estrogen levels, or which antagonises the estrogen receptor.
- an agent which lowers estrogen levels, or which antagonises the estrogen receptor may be administered in combination with an agent which lowers estrogen levels, or which antagonises the estrogen receptor.
- a pharmaceutical product containing a compound of formula (I) or derivative as herein defined and one or more agents which lower estrogen levels, or antagonise the estrogen receptor, as a combined preparation for simultaneous, separate or sequential use in the treatment of endometriosis.
- Agents which lower estrogen levels include gonadotropin releasing hormone (GnRH) agonists, GnRH antagonists and estrogen synthesis inhibitors.
- Agents which antagonise the estrogen receptor, i.e. estrogen receptor antagonists, include anti-estrogens, or agents which selectively agonise the beta subtype of the estrogen receptor (ER ⁇ agonists).
- GnRH agonists suitable for the present invention include leuprorelin (Prostap - Wyeth), buserelin (Suprefact - Shire), goserelin (Zoladex - Astra Zeneca), triptorelin (De-capeptyl - Ipsen), nafarelin (Synarel - Searle), deslorelin (Somagard - Sh ire), and h istrel in/supprelin (Ortho Pharmaceutical Corp/Shire).
- GnRH antagonists suitable for the present invention include teverelix (also known as antarelix), abarelix (Plenaxis - Praecis Pharmaceuticals Inc.), cetrorelix (Cetrotide - ASTA Medica), ganirelix (Orgalutran - Organon), ozarelix (Spectrum) and elagolix (Neurocrine Biosciences Inc).
- Anti-estrogens suitable for the present invention include tamoxifen, Faslodex (Astra Zeneca), idoxifene (see Coombes et al. (1995) Cancer Res. 55, 1070- 1074), raloxifene or EM-652 (Labrie, F et al, (2001 ) J steroid Biochem MoI Biol, 79, 213).
- ER ⁇ agonists suitable for the present invention include phnaberel (ERB-041 ) and ERB-196 (Wyeth).
- Estrogen synthesis inhibitors suitable for the present invention include aromatase inhibitors.
- aromatase inhibitors include Formestane (4-OH androstenedione), Exemestane, Anastrozole (Ahmidex) and Letroxole.
- the compounds of formula (I) or derivative as herein defined of the present invention may be administered in combination with an alpha-2-delta ligand.
- a pharmaceutical product containing a compound of formula (I) or derivative as herein defined and one or more alpha-2-delta ligands, as a combined preparation for simultaneous, separate or sequential use in the treatment of endometriosis.
- alpha-2-delta ligands for use in the present invention are those compounds, or pharmaceutically acceptable salts thereof, generally or specifically disclosed in US4024175, particularly gabapentin, EP641330, particularly pregabalin, US5563175, WO-A-97/33858, WO-A-97/33859, WO- A-99/31057, WO-A-99/31074, WO-A-97/29101 , WO-A-02/085839, particularly [(1 R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-y I ] a c e t i c acid, W O-A- 99/31075, p articularly 3-(1-aminomethyl-cyclohexylmethyl)-4H-
- [1,2,4]oxadiazol-5-one a n d C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]- methylamine, WO-A-99/21824, particularly (3S,4S)-(1-aminomethyl-3,4- dimethyl-cyclopentyl)-acetic acid, WO-A-01/90052, WO-A-01/28978, particularly (1 ⁇ ,3 ⁇ ,5 ⁇ )(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid , EP0641330, WO-A-98/17627, WO-A-00/76958, particularly (3S.5R)- 3-aminomethyl-5-methyl-octanoic acid, WO-A-03/082807, particularly (3S,5R)-3-amino-5-methyl-h eptanoic acid, (3S,5R)-3-amino-5-methyl- nonanoic
- Preferred alpha-2-delta ligands for use in the combination of the present invention include: gabapentin, pregabalin, [(1 R,5R,6S)-6- (aminomethyl)bicyclo[3.2.0]hept-6-y I ] a c e t i c acid, 3-(1 -aminomethyl- cyclohexylmethyl)-4H-[1 ,2,4]oxadiazol-5-one, C-[1 -(1 H-tetrazol-5-ylmethyl)- cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)- acetic acid, (1 ⁇ ,3 ⁇ ,5 ⁇ )(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3
- alpha-2-delta ligands for use in the combination of the present invention are (3S,5R)-3-amino-5-methyloctanoic acid, (3S,5R)-3- amino-5-methylnonanoic acid, (3R,4R,5R)-3-amino-4,5-dimethylheptanoic acid and (3R,4R,5R)-3-amino-4,5-d i m ethyloctano ic acid , a nd th e pharmaceutically acceptable salts thereof.
- alpha-2-delta ligands for use in the combination of the present invention are selected from gabapentin, pregabalin, (1 ⁇ ,3 ⁇ ,5 ⁇ )(3- amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (2S,4S)-4-(3- chlorophenoxy)proline and (2S,4S)-4-(3-fluorobenzyl)proline or pharmaceutically acceptable salts thereof.
- alpha-2-delta ligands for use in the combination of the present invention are gabapentin, pregabalin, 3-methylgabapentin, (1 ⁇ ,3 ⁇ ,5 ⁇ )(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)- 3-aminomethyl-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic a c i d , ( 3 S , 5 R )-3-amino-5-methyl-o c t a n o i c a c i d , ( 2 S , 4 S )-4-(3- chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)-proline, [(1 R,5R,6S)-6- (aminomethyl)bicyclo[3.2.0]hept-6-y I ] a
- Microtubule modulator e.g. Microtubule stabilizer
- Microtubule modulator e.g. Microtubule stabilizer
- the compounds of the invention may have the advantage that they are more potent, have a longer duration of action, have a broader range of activity, are more stable, have fewer side effects or are more selective, or have other more useful properties than the compounds of the art.
- (x) a method of treatment of a mammal to treat endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain) or chronic pelvic pain syndrome including treating said mammal with an effective amount of compound of formula (I) or a pharmaceutically acceptable salt, solvate (including hydrate), or prodrug thereof as herein defined or composition thereof; (xi) a method as in (x) where the disease or disorder is endometriosis and/or uterine fibroids (leiomyomata);
- compounds of formula (I) or derivatives as herein defined of the invention will be administered as a formulation in association with one or more pharmaceutically acceptable excipients, diluents or carriers.
- excipient is used herein to describe any ingredient other than the compound(s) of the invention.
- the choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
- compositions suitable for the delivery of the compounds of formula (I) or derivatives as herein defined of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in "Remington's Pharmaceutical Sciences", 19th Edition (Mack Publishing Company, 1995).
- the compounds of formula (I) or derivatives as herein defined of the invention may be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid, semi-solid and liquid systems such as tablets; soft or hard capsules containing multi- or nano- particulates, liquids, or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- Liquid formulations include suspensions, solutions, syrups and elixirs.
- Such formulations may be employed as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents.
- a carrier for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents.
- Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- the compounds of formula (I) or derivatives as herein defined of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, IJ. (6), 981 -986, by Liang and Chen (2001 ).
- the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form.
- tablets generally contain a disintegrant.
- disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate.
- the disintegrant will comprise from 1 weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the dosage form.
- Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
- lactose monohydrate, spray-dried monohydrate, anhydrous and the like
- mannitol xylitol
- dextrose sucrose
- sorbitol microcrystalline cellulose
- starch dibasic calcium phosphate dihydrate
- Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
- surface active agents such as sodium lauryl sulfate and polysorbate 80
- glidants such as silicon dioxide and talc.
- surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.
- Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
- Lubricants generally comprise from 0.25 weight % to 10 weight %, preferably from 0.5 weight % to 3 weight % of the tablet.
- ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
- Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.
- Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt- granulated, melt congealed , or extruded before tabletting .
- the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
- Consumable oral films are typically pliable water-soluble or water-swellable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise a compound of formula (I) or derivative as herein defined, a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabiliser or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function.
- the film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range 0.01 to 99 weight %, more typically in the range 30 to 80 weight %.
- ingredients include anti-oxidants, colorants, flavourings and flavour enhancers, preservatives, salivary stimulating agents, cooling agents, co-solvents (including oils), emollients, bulking agents, anti-foaming agents, surfactants and taste-masking agents.
- Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.
- Solid formulations for oral administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in "Pharmaceutical Technology On-line", 25(2), 1-14, by Verma et al (2001 ). The use of chewing gum to achieve controlled release is described in WO 00/35298.
- the compounds of formula (I) or derivatives as herein defined of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
- Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous.
- Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9)
- a suitable vehicle such as sterile, pyrogen-free water.
- parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- solubility of compounds of formula (I) or derivatives as herein defined used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility- enhancing agents.
- Formulations for parenteral administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- compounds of the invention may be formulated as a suspension or as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound .
- examples of such formulations include drug-coated stents and semi-solids and suspensions comprising drug-loaded poly(c//-lactic-coglycolic)acid (PGLA) microspheres.
- PGLA poly(c//-lactic-coglycolic)acid
- the compounds of formula (I) or derivatives as herein defined of the invention may also be administered topically, (intra )dermally, or transdermal ⁇ to the skin or mucosa.
- Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used.
- Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
- Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955-958, by Finnin and Morgan (October 1999).
- Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. PowderjectTM, BiojectTM, etc.) injection.
- Formulations for topical administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- the compounds of formula (I) or derivatives as herein defined of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with l actose , or as a m ixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a su itable propel lant, such as 1 , 1 , 1 ,2- tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3-heptafluoropropane, or as nasal drops.
- the powder may comprise a bioadhesive agent, for example, chitosan
- the pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- the drug product Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
- Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as /-leucine, mannitol, or magnesium stearate.
- the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
- suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
- a suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 ⁇ g to 20 mg of the compound of the invention per actuation and the actuation volume may vary from 1 ⁇ l_ to 100 ⁇ l_.
- a typical formulation may comprise a compound of formula (I) or derivative as herein defined, propylene glycol, sterile water, ethanol and sodium chloride.
- Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
- Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
- Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- the compounds of formula (I) or derivatives as herein defined of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
- Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- the compounds of formula (I) or derivatives as herein defined of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
- the compounds of formula (I) or derivatives as herein defined of the invention may also be administered vaginally via a vaginal ring.
- vaginal ring examples of formulations of vaginal ring are described in US 5,972,372; US 6,126,958; and US 6,125,850.
- Use of the vaginal ring is timed to the cycle to which the compound is being administered, including a 28-day cycle. However, it can be inserted for a longer or shorter period of time. For example, the ring can be inserted into the vagina to remain in place for three consecutive weeks. During the fourth week, the vaginal ring is removed and menses occurs. The following week, a new ring can be inserted and worn for the next consecutive three weeks then removed for the next menses to occur.
- the vaginal ring can be replaced weekly for three consecutive weeks, followed by a week without the ring during menses. Regimens including longer and shorter cycles are also envisaged.
- Drug-cyclodextrin complexes are found to be generally useful for most dosage forms and administration routes. Both inclusion and non- inclusion complexes may be used.
- the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/1 1172, WO 94/02518 and WO 98/55148.
- two or more pharmaceutical compositions at least one of which contains a compound of formula (I) or derivative as herein defined in accordance with the invention, m ay conven i en tl y b e com b i n ed i n th e form of a k it suitable for coadministration of the compositions.
- the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) or derivative as herein defined in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
- a container, divided bottle, or divided foil packet An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
- the kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
- the kit typically comprises directions for administration and may be provided with a so-called memory aid.
- the total daily dose of the compound of formula (I) or derivative as herein defined of the invention is typically in the range ⁇ 1 mg to 1000 mg depending, of course, on the mode of administration.
- oral administration may require a total daily dose of from ⁇ 1 mg to 1000 mg, while an intravenous dose may only require from ⁇ 1 mg to 500 mg.
- the total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein.
- These dosages are based on an average human subject having a weight of about 60 kg to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
- treating means to alleviate symptoms, eliminate the causation either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms.
- treatment includes alleviation, elimination of causation (either on a temporary or permanent basis) of, or prevention of symptoms and disorders associated with endometriosis and/or uterine leiomyoma.
- the treatment may be a pre- treatment as well as a treatment at the on-set of symptoms.
- the compounds of the present invention should be useful for the treatment of gynaecological symptoms of painful menstruation (dysmenorrhoea), painful intercourse (dyspareunia), painful defaecation (dyzchexia) or micturition (dysuria) provoked by menstruation, chronic pelvic pain (constant or cyclic painful symptoms present for more than six months), excessive menstrual blood loss (menorrhagia), frequent periods (polymenorrhagia) or infrequent or irregular periods (oligoamenorrhoea or amenorrhoea) either occurring in the absence of specific pathology (dysfunctional uterine bleeding and/or primary dysmenorrhoea), or in association with endometriosis, adenomyosis, polycystic ovarian syndrome, or uterine fibroids (leiomyomata).
- treatment encompasses not only the management of the pain symptoms associated with the abovementioned conditions, but also modification of the disease progression itself, i.e. a clinically meaningful benefit to the patients is achieved.
- Modification of disease progression may result in reduction or elimination of pain. More preferably, modification of disease progression may result in reduction or elimination of pain, and prolonged intervals to symptom onset. Even more preferably, modification of disease progression may result in reduction or elimination of pain, prolonged intervals to symptom onset, and reduction in the need for surgery. Most preferably, modification of disease progression may result in reduction or elimination of pain, prolonged intervals to symptom onset, a reduction in the need of surgery, and preserved and/or improved fertility.
- the assay for PR antagonism takes advantage of the extensively reported modulation of alkaline phosphatase (AP) expression in human breast T47D mammary carcinoma cells ⁇ Beck et al., D. P. (1993).
- the progesterone antagonist RU486 acquires agon ist activity upon stimulation of cAMP signalling pathways. Proc Natl Acad Sci USA 90, 4441-4445; Fensome et al. (2002) . New progesterone receptor antagonists: 3,3-disubstituted-5- aryloxindoles. Bioorg Med Chem Lett 12, 3487-3490; Zhang et al., (2002a).
- 6-Aryl-1 ,4-dihydro-benzo d 1 ,3 oxazin- 2-ones a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists. Journal of Medicinal Chemistry 45, 4379-4382; Zhang et al., (2003). Novel 6- aryl-1 ,4-dihydrobenzo d oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists. Bioorganic & Medicinal Chemistry Letters 13, 1313-1316; Zhang et al., (2002b). Potent nonsteroidal progesterone receptor agon ists: synthesis and SAR study of 6-aryl benzoxazines.
- T47D cells are grown by propagating in DMEM with phenol red + 10% FCS + 2 mM Glutamine at 37 °C/5% CO 2 .
- the media is exchanged for phenol red free DMEM + 5% CS-FCS (Assay media).
- Cells are incubated overnight in assay media then harvested and frozen in assay media containing 10% DMSO at 1.5e7 cells/mL in 2 ml_ aliquots using a Planer and immediately stored in liquid nitrogen. Vials are removed from liquid nitrogen storage and immediately thawed in a water bath at 37 0 C.
- the cell suspension is added dropwise to 20 ml_ of assay media, then the tube centhfuged at 1000 rpm for 4 minutes, the supernatant is discarded and the pellet re-suspended in 20 ml_ assay media.
- T47D cells are then plated at 8750 cells/well in 35 ⁇ l_ assay media in sufficient white solid 384 well TC plates for the assay.
- For the agonist format assay a further 10 ⁇ L of assay media is added to each well. These plates are then cultured for 3-6 hours at 37 °C/5% CO 2 before compound addition.
- Test substances are prepared by in 100% DMSO, half log concentrations from 4 mM in 384 well plates 5 ⁇ L / well (referred to here as grandmother plates').
- Progesterone is 100 ⁇ M made up in ethanol and PBS (i.e. add 1 ml_ ethanol to progesterone initially to help dissolving) and stored in 0.5-1 ml_ aliquots at -20 0 C.
- Max's & Min's are prepared as below in Falcon tubes and then 100 ⁇ l_ is transferred to the appropriate wells of a 384 well plate: Agonist Max: (solid block on plate map) 10 uM progesterone (FAC
- Agonist Min (checker pattern on plate map) Diluent
- Antagonist Max (solid block on plate map) Diluent
- Antagonist Min (checker pattern on plate map) 1 uM RU -486 (FAC
- 25 nM progesterone in assay media is prepared from 100 ⁇ M stock (12.5 ⁇ l_ progesterone / 50 ml_ media), from which 10 ⁇ l_ per well is transferred to the assay plate using the PlateMate Plus (already containing cells & compound).
- the cell plates are incubated @ 37 0 C, 5% CO2 overnight (at least 16 hours). Then: • Tap out media from cell plates and drain on tissue . Wash with PBS 40 ⁇ L/well
- results are expressed as alkaline phosphatase induction (% of maximal progesterone response) by the test substances is achieved and an EC 5 O is determined.
- results are expressed as alkaline phosphatase inhibition by the test compounds and an IC 5 O is determined
- the EC 5 O value is defined as the drug concentration required to produce a 50% induction of AP activity compared with 5 nM progesterone alone. Test substances with full agonism achieve 100% of the response of progesterone whereas partial agonists induce AP activity to a level which is sub-maximal to that induced by progesterone.
- the IC 5 O value is defined as the drug concentration required to produce a 50% inhibition of AP activity compared with 5 nM progesterone alone.
- K 1 calculation was carried out on the resulting IC50 data using the Cheng- Prusoff equation. In binding assays the concentration of antagonist required to displace 50% of a radiolabeled l igand from a receptor preparation is measured as IC50. This is dependent on the concentration of radiolabeled ligand and as such is converted to Ki using the Cheng-Prusoff equation below.
- K 1 is an estimation of the concentration of antagonist at which 50% of the receptors are occupied.
- the Cheng-Prusoff equation used in binding assays is often used to calculate a K 1 derived from IC50 for functional assays substituting agonist concentration (A) for L and the agonist EC50 for K d .
- the Ki values are less than 5 ⁇ M. In a preferred embodiment, the Ki value is less than 500 nM. In a more preferred embodiment, the Ki value is less than 50 nM.
- the present invention also encompasses any one or more of these processes for preparing the compounds of formula (I) or derivatives as herein defined, in addition to any novel intermediates used therein.
- the compounds of formula (Ia) can be prepared from the compounds of formula (III) and formula (II) by in situ acylation in the presence of a suitable base, such as pyridine or thethylamine (step (N)).
- a suitable base such as pyridine or thethylamine
- Typical conditions comprise using from 1 to 2 molar equivalents of a compound of formula (II), from 1 to 5 molar equivalents of pyridine, in an organic solvent, at a temperature of from - 20 to 80 0 C.
- Preferred conditions comprise 1.2 molar equivalents of a compound of formula (II) and 2 molar equivalents of thethylamine in 2- methyltetrahydrofuran, at ambient room temperature.
- the compounds of formula (III) can be prepared from the compounds of formula (IV) by acid chloride formation with a suitable reagent, such as thionyl chloride or oxalyl chloride (step (i)).
- a suitable reagent such as thionyl chloride or oxalyl chloride (step (i)).
- Typical conditions comprise an excess of thionyl chloride at a temperature of from 20 to 80 0 C.
- Preferred conditions comprise an excess of thionyl chloride at a temperature of 80 0 C.
- the compounds of formula (Ia) can be prepared from the compounds of formula (IV) and formula (II) by amide coupling in the presence of a suitable coupling reagent, such as 1 -propanephosphonic acid cyclic anhydride, 1 -hydroxybenzotriazole hydrate, 1 ,1 '-carbonyldiimidazole or O- benzotriazol-1 -yl-N,N,N',N'-tetramethyluronium hexafluorophosphate, and a suitable base, such as triethylamine or pyridine, in an organic solvent (step (iii)).
- a suitable coupling reagent such as 1 -propanephosphonic acid cyclic anhydride, 1 -hydroxybenzotriazole hydrate, 1 ,1 '-carbonyldiimidazole or O- benzotriazol-1 -yl-N,N,N',N'-tetramethyluronium hexafluor
- Typical conditions comprise using from 1 to 3 molar equivalents of a compound of formula (II), from 1 to 3 molar equivalents of O-benzotriazol-1 -yl- N,N,N',N'-tetramethyluronium hexafluorophosphate and from 1 to 5 molar equivalents of pyridine, in 2-methyltetrahydrofuran, at a temperature of from 0 0 C to 80 0 C.
- Preferred conditions comprise 1.3 molar equivalents of a compound of formula (II), 2 molar equivalents of O-benzotriazol-1-yl- N,N,N',N'-tetramethyluronium hexafluorophosphate and 3 molar equivalents of pyridine, in 2-methyltetrahydrofuran, at a temperature of 80 0 C.
- the compounds of formula (IV) can be prepared from the compounds of formula (Vl) by carboxylation with carbon dioxide in the presence of a suitable base, such as n-butyllithium, sec-butyllithium or te/t-butyllithium (step (v)).
- a suitable base such as n-butyllithium, sec-butyllithium or te/t-butyllithium (step (v)).
- Typical conditions comprise using an excess of carbon dioxide in the presence of from 1 to 3 molar equivalents of n-butyllithium, in an organic solvent, at a temperature of from -100 to 20 0 C.
- Preferred conditions comprise using an excess of carbon dioxide in the presence of 1.5 molar equivalents of n-butyllithium, in tetrahydrofuran, at a temperature of -78 0 C.
- the compounds of formula (IV) can be prepared from the compounds of formula (V) (where R E is a suitable ester-forming group, e.g. C-1-10 alkyl, phenyl optionally substituted by from 1 to 3 substituents each independently selected from Ci- ⁇ alkyl, halo and nitro, or phenylmethyl optionally substituted in the phenyl ring by from 1 to 3 substituents each independently selected from Ci- ⁇ alkyl, halo and nitro) by hydrolysis with a suitable base, such as sodium hydroxide or lithium hydroxide (step (viii)).
- R E is a suitable ester-forming group, e.g. C-1-10 alkyl, phenyl optionally substituted by from 1 to 3 substituents each independently selected from Ci- ⁇ alkyl, halo and nitro
- a suitable base such as sodium hydroxide or lithium hydroxide
- Typical conditions comprise using from 1 to 5 molar equivalents of sodium hydroxide in a suitable protic solvent and water, at a temperature of from 20 to 100 0 C.
- Preferred conditions comprise 1 .5 molar equivalents of sodium hydroxide in a water/methanol mix at a temperature of 100 0 C.
- the compounds of formula (V) can be prepared from the compounds of formula (Vl) by carbonylation with a carbon monoxide source in the presence of a suitable catalyst and base, using a suitable alcohol as solvent (step (vii)).
- Typical conditions comprise using from 0.01 to 0.20 molar equivalents of [1 ,1 '- bis(diphenylphosphino)ferrocene] palladium (II) chloride and from 1 to 5 molar equivalents of triethylamine, in methanol, charged to between 15 and 300 psi (103 to 207OkPa) with carbon monoxide, at a temperature of from 20 to 150 0 C.
- Preferred conditions comprise using 0.05 molar equivalents of [1 ,1 '- bis(diphenylphosphino)ferrocene] palladium (I I) chloride and 2 molar equivalents of triethylamine, in methanol, charged to I OOpsi (69OkPa) with carbon monoxide, at a temperature of 100 0 C.
- the compounds of formula (Vl) can be prepared from the compounds of formula (VII) by a Sandmeyer reaction with a suitable reagent, such as 'butyl nitrite, isoamyl nitrite or a sodium nitrite, in the presence of a suitable acid, such as acetic acid or concentrated sulphuric acid, and in the presence of a su itable iod ide source, such as potassium iod ide, copper iod ide or diiodomethane.
- a suitable reagent such as 'butyl nitrite, isoamyl nitrite or a sodium nitrite
- a suitable acid such as acetic acid or concentrated sulphuric acid
- a su itable iod ide source such as potassium iod ide, copper iod ide or diiodomethane.
- Typical conditions comprise usin from 1 to 5 molar equivalents of 'butyl nitrite in the presence of from 1 to 10 molar equivalents of acetic acid and from 1 to 5 molar equivalents of potassium iodide, in a suitable solvent, at a temperature of from -40 to 80 0 C.
- Preferred conditions comprise 2.5 molar equivalents of 'butyl nitrite in the presence of 3 molar equivalents of acetic acid and 2.5 molar equivalents of potassium iodide, in acetonitrile and water, at ambient room temperature.
- X is a su itable leaving group, such as chloro, iodo, bromo, methanesulphonyloxy or tosyl).
- the compounds of formula (VII) can be prepared from the compounds of formula (VIII) and formula (IX) by pyrazole ring formation in the presence of a suitable base, such as triethylamine or diisopropylethylamine, and an acid, such as acetic acid, with or without a catalytic amount of a strong acid, such as thfluoroacetic acid, in a suitable organic solvent (step (ix)).
- Typical conditions comprise using from 1 to 10 molar equivalents of a compound of formula (VIII), from 1 to 20 molar equivalents of diisopropylethylamine, from 6 to 60 molar equivalents of acetic acid, in ethanol, at from 0 0 C to 78 0 C.
- Preferred conditions comprise 1.1 molar equivalents of a compound of formula (VIII), 2 molar equivalents of diisopropylethylamine, and 6 molar equivalents of acetic acid, in ethanol at 60 0 C.
- the compounds of formula (VII) can be prepared from the compounds of formula (X) by deprotection in the presence of a suitable hydrazine reagent, such as hydrazine hydrate or methylhydrazine, in a suitable organic solvent (step (xiii)).
- Typical conditions comprise using from 1 to 5 molar equivalents of methylhydrazine, in tetrahydrofuran, at from -20 0 C to 67 0 C .
- P r eferred conditions comprise 1 molar equivalent of methylhydrazine, in tetrahydrofuran, at ambient room temperature.
- the compounds of formula (X) can be prepared from the compounds of formula (Xl) and formula (XII) by alkylation in the presence of a suitable base
- Typical conditions comprise using from 1 to 3 molar equivalents of a compound of formula (Xl), and from 1 to 5 molar equivalents of potassium carbonate, in acetonitrile, at from 0 to 82 0 C.
- Preferred conditions comprise 1.1 molar equivalents of a compound of formula (Xl), and 3 molar equivalents of potassium carbonate, in acetonitrile, at 80 0 C.
- the compounds of formula (XII) can be prepared from the compounds of formula (XIII), by protection, using phthalic anhydride in a suitable organic solvent (step (xi)).
- Typical conditions comprise using from 1 to 3 molar equivalents of phthalic anhydride, in 1 ,4-dioxan, at from -20 0 C to 100 0 C.
- Preferred conditions comprise 1.14 molar equivalents of phthalic anhydride, in 1 ,4-dioxan, at ambient room temperature.
- the compounds of formula (XIII) can be prepared from the compounds of formula (IX) and hydrazine by pyrazole formation in the presence of an acid catalyst, such as acetic acid or trifluoroacetic acid, in an organic solvent (step (x)).
- an acid catalyst such as acetic acid or trifluoroacetic acid
- Typical conditions comprise using from 1 to 3 molar equivalents of hydrazine hydrate, and from 0.01 to 0.2 molar equivalents of trifluoroacetic acid, in ethanol, at from -20 0 C to 78 0 C.
- Preferred conditions comprise using 1.1 molar equivalents of hydrazine hydrate and 10% trifluoroacetic acid, in ethanol, at ambient room temperature.
- Y is a suitable halide or triflate and R 3 5 0 A A is a suitable ester-forming group, e.g. C MO alkyl, phenyl optionally substituted by from 1 to 3 substituents each independently selected from Ci-6 alkyl, halo and nitro, or phenylmethyl optionally substituted in the phenyl ring by from 1 to 3 substituents each independently selected from Ci-6 alkyl, halo and nitro).
- Y is a suitable halide or triflate and R 3 5 0 A A is a suitable ester-forming group, e.g. C MO alkyl, phenyl optionally substituted by from 1 to 3 substituents each independently selected from Ci-6 alkyl, halo and nitro, or phenylmethyl optionally substituted in the phenyl ring by from 1 to 3 substituents each independently selected from Ci-6 alkyl, halo and nitro).
- the compounds of formulae (XVI) and (XVIII) are known compounds.
- the compounds of formula (IX) can be prepared from the compounds of formula (XIV) and (XV) by ⁇ -cyano-ketone formation in the presence of a base, such as lithium diiospropylamide, potassium tert butoxide or sodium hydride, in an organic solvent (step (xv)).
- a base such as lithium diiospropylamide, potassium tert butoxide or sodium hydride
- Typical conditions comprise using from 1 to 3 molar equivalents of a compound of formula (XIV) and from 1 to 3 molar equivalents of lithium diisopropylamide, in tetrahydrofuran, at from -100 0 C to 25 0 C.
- Preferred conditions comprise 1 molar equivalent of a compound of formula (XIV) and 1.5 molar equivalents of lithium diiospropylamide, in tetrahydrofuran at -78 0 C.
- the compounds of formula (XV) are known compounds and can be prepared from the compounds of formula (XVI) cyanation with a suitable cyanide source, such as zinc cyanide, in the presence of a suitable palladium catalyst, in a suitable organic solvent (step (xiv)).
- Typical conditions comprise using from 0.5 to 2 molar equivalents of zinc cyanide, from 0.01 to 0.2 molar equivalents of ths-(dibenzylideneacetone) dipalladium and from 0.02 to 0.3 molar equivalents of 1 ,1 'bis(diphenylphosphino)ferrocene, in dimethylformamide, at from 25 0 C to 153 0 C.
- Preferred conditions comprise 0.6 molar equ ivalents of zinc cyan ide, 0.1 molar equivalents tris- (dibenzylideneacetone) dipalladium and 0.2 molar equivalents 1 ,1 'bis(diphenylphosphino)ferrocene, in dimethylformamide, at 153 0 C.
- the compounds of formula (XV) can be prepared from the compounds of formula (XVII) by carbonylation with a carbon monoxide source in the presence of a suitable catalyst and base, using a suitable alcohol as solvent (step (xvii)).
- Typical conditions comprise using from 0.01 to 0.20 molar equivalents of [1 ,1 '-bis(diphenylphosphino)ferrocene] palladium (II) chloride and from 1 to 5 equivalents of triethylamine, in methanol, charged to between 15 and 300 psi (103 to 207OkPa) with carbon monoxide, at a temperature of from 20 to 150 0 C.
- Preferred conditions comprise 0.05 molar equivalents of [1 ,1 '-bis(diphenylphosphino)ferrocene] palladium (II) chloride and 2 molar equivalents of triethylamine, in methanol, charged to I OOpsi (69OkPa) with carbon monoxide, at a temperature of 100 0 C.
- the compounds of formula (XVII) can be prepared from the compounds of formula (XVIII) by triflation with a suitable agent, such as trifluoromethane sulfonic anhydride, in the presence of a suitable base, such as triethylamine or pyridine (step (xvi)).
- a suitable agent such as trifluoromethane sulfonic anhydride
- a suitable base such as triethylamine or pyridine
- Typical conditions comprise using from 1 to 2 molar equivalents of trifluoromethane sulfonic anhydride and from 1 to 5 molar equivalents of base, in an organic solvent, at a temperature of from -78 0 C to 0 0 C.
- Preferred conditions comprise 1.2 molar equivalents of trifluoromethane su lfon ic a n hyd rid e and 2 molar equivalents of triethylamine, in dichloromethane at -15 0 C.
- the compounds of formula (XX) can be prepared from the compounds of formula (XIX) by cyanation with a suitable cyanide source, such as zinc cyanide, in the presence of a suitable palladium catalyst, in a suitable organic solvent (step (xix)).
- a suitable cyanide source such as zinc cyanide
- Typical conditions comprise using from 0.5 to 2 molar equivalents of zinc cyanide, from 0.01 to 0.2 molar equivalents of tris- (dibenzylideneacetone) dipalladium and from 0.02 to 0.3 molar equivalents of 1 ,1 'bis(diphenylphosphino)ferrocene, in dimethylformamide, at a temperature of from 25 0 C to 153 0 C.
- Preferred conditions comprise 0.6 molar equivalents of zinc cyanide, 0.1 molar equivalents ths-(dibenzylideneacetone) dipalladium and 0.2 molar equivalents 1 ,1 'bis(diphenylphosphino)ferrocene, in dimethylformamide, at 153 0 C.
- the compounds of formula (XIX) can be prepared from the compounds of Formula (Vila) by halogenation with a suitable reagent such as N- iodosuccimide (step (xviii)).
- Typical conditions comprise using from 1 to 2 molar equivalents of N-iodosuccimide in an organic solvent, at a temperature of from 20 to 100 0 C.
- Preferred conditions comprise 1 .2 molar equivalents of N-iodosuccimide in acetonitrile at 82 0 C.
- the compounds of formula (XIX) can be prepared from the compounds of Formula (Vila) by halogenation with a suitable reagent, such potassium chloride, in the presence of Oxone ® (trade mark) (potassium peroxymonosulfate)
- a suitable reagent such potassium chloride
- Oxone ® trade mark
- Typical conditions comprise using from 1 to 2 molar equivalents of potassium chloride and from 1 to 2 molar equivalents of Oxone ® in an organic solvent, at a temperature of from 0 to 80 0 C.
- Preferred conditions comprise 1.1 molar equivalents of potassium chloride and 1.1 molar equivalents of Oxone ® in acetonithle at 20 0 C.
- reaction times, number of equivalents of reagents and reaction temperatures may be modified for each specific reaction, and that it may nevertheless be necessary or desirable to employ different work-up or purification conditions.
- Example 1A 3-(4-Cyano-phenyl)-4-cyclopropyl-N-(2-hydroxy-2- methylpropyl)-1 -isopropyl-1 H-pyrazole-5-carboxamide
- O-Benzothazol-1 -yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (642 mg, 1.69 mmol) was added to a solution of the compound described in Preparation 5 (250 mg, 0.85 mmol) in 2-methyl tetrahydrofuran (5 ml_), followed by pyridine (0.21 ml_, 2.54 mmol) and (R)-(+)-N-Boc-3- aminopyrrolidine (0.19 ml_, 1.10 mmol). This mixture was stirred at relux for 1 hour and then allowed to stand at room temperature for 16 hours. The mixture was evaporated under reduced pressure to give a gum.
- Example 12 3-(4-Cyanophenyl)-4-cyclopropyl-1-isopropyl-N-[(3S)-1 - propionylpyrrolidin-3-yl]-1 H-pyrazole-5-carboxamide
- Example 13 3-(4-Cyanophenyl)-4-cyclopropyl-1 -isopropyl-N-[(3R)-1 - (methylsulfonyl) pyrrolin-3-yl]-1 H-pyrazole-5-carboxamide
- Example 17 3-(4-Cyanophenyl)-4-cyclopropyl-1 -isopropyl-N-(1 -propionyl azetidin-3-yl)-1 H-pyrazole-5-carboxamide
- Example 18 3-(4-Cyanophenyl)-4-cyclopropyl-1 -isopropyl-N-[1 -(methyl sulfonyl) azetidin-3-yl]-1 H-pyrazole-5-carboxamide
- Example 19 N-(1 -Acetylazetidin-3-yl)-3-(4-cyanophenyl)-4-cyclopropyl-1 - isopropyl-1 H-pyrazole-5-carboxamide
- Example 22 3-(4-Cyanophenyl)-4-cyclopropyl-1 -isopropyl-N-(3,3,3-trifluoro propyl)-1 H-pyrazole-5-carboxamide
- Example 35 3-(4-Cyanophenyl)-4-cyclopropyl-1 -isopropyl-N-[(1 R)- 1 ⁇ methylpropyl]-1 H-pyrazole-5-carboxamide
- Example 38 3-(4-Cyanophenyl)-4-cyclopropyl -N-[(6R)-6,7-dihydro-5H- pyrrolo[1 ,2-a]imidazol-6-yl]-1 -isopropyl-1 H-pyrazole-5-carboxamide
- Example 48 3-(4-Cyanophenyl)-4-cyclopropyl-1 -isopropyl-N-(2,2,2-trifluoro ethyl )-1 H-pyrazole-5-carboxamide
- Triethylamine (0.16 mL, 1.22 mmol) was added to a solution of either the compound described in Example 2, or Example 3, or a mixture thereof (215 mg, 0.61 mmol), in dimethyl sulphoxide (10 mL) followed by a solution of sulphur trioxide pyridine complex (0.19 g, 1 .22 mmol) in dimethyl sulphoxide
- Example 80 3-(4-Cyanophenyl)-N-(2-hydroxy-2-methylpropyl)-4-methyl-1 - (tetrahydrofuran-3-yl)-1 H-pyrazole-5-carboxamide
- Example 106 1 -sec-Butyl-3-(4-cyanophenyl)-4-ethyl-N-(2-hydroxy-2- methylpropyl)-1 H-pyrazole-5-carboxamide
- Example 109 1 -sec-Butyl-3-(4-cyanophenyl)-4-ethyl-N-[2-(methylamino)-2- oxoethyl]-1 H-pyrazole-5-carboxamide
- Example 111 3-(4-Cyanophenyl)-N-cyclopropyl-4-ethyl-1 -isopropyl-1 H- pyrazole-5-carboxamide
- Example 120 3-(4-Cyano-3-methylphenyl)-4-cyclopropyl-1-isopropyl-N-[2- (nnethylannino)-2-oxoethyl]-1 H-pyrazole-5-carboxannide
- Benzotriazol-1-yloxy-tris(dinnethylannino)phosphoniunn hexafluorophosphate (86 mg, 0.19 mmol) was added to a solution of the compound described in Preparation 64 (50 mg, 0.16 mmol) and H-GIy-NHMe hydrochloride (24 mg, 0.19 mmol) in N,N-dimethylformamide (1 ml_), cooled to 5 0 C, followed by diisopropylethylamine (0.23 ml_, 0.65 mmol). This mixture was stirred at room temperature for 16 hours.
- reaction mixture was then diluted with ethyl acetate (25 ml_), and washed with a 10% w/v aqueous solution of citric acid (10 ml_), followed by a saturated aqueous solution of sodium hydrogen carbonate (10 ml_) and brine (10 ml_).
- the organic extracts were dried over magnesium sulphate, filtered, and evaporated under reduced pressure to give a gum.
- This crude residue was purified by column chromatography eluting with 30% dichloromethane in ethyl acetate to give the title compound as a solid (0.042 g, 68%).
- Examples 121 -134 were prepared using similar procedures to those described in Examples 1 , 77 and 89 using intermediates prepared in Preparations 5, 23, 36, 59 and 72-78.
- Acetic acid (6.45 ml_, 113 mmol) was added to a cooled (0 0 C) solution of the compound described in Preparation 2 (1 O g, 37.5 mmol) in acetonithle (150 ml_). This cooled solution was allowed to stir for 15 minutes after which time a solution of potassium iodide (15.6 g, 93.9 mmol) in water (50 ml_) was added followed by a solution of te/t-'butyl nitrite (11.2 ml_, 93.9 mmol) in acetonitrile
- Pottasium Ferrocyanide trihydrate (3.70 g, 17.5 mmol) was added to a solution of 4-bromo-3-nnethyl-benzoic acid methyl ester (4.00 g, 17.46 mmol) in dimethylacetamide (10 ml_), followed by sodium carbonate (1 .85 g, 17.5 mmol) and palladium acetate (78 mg, 0.35 mmol). This mixture was heated at 12O 0 C for 15 hours, after which time it was quenched onto water (150 ml_) and extracted with tert-butylmethylether (3 x 50 ml_).
- N-lodosuccimide (1.73 g, 7.69 mmol) was added to a solution of the compound described in Preparation 31 (1.45 g, 6.41 mmol) in acetonitrile (25.6 ml_). This mixture was refluxed for 4 hours and then allowed to stand at room temperature for 16 hours. It was then concentrated under reduced pressure and the crude residue was partitioned between water (50 ml_) and ethyl acetate (3 x 50 ml_). The combined organic extracts were dried over magnesium sulphate, filtered, and evaporated under reduced pressure to give a solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009294290A AU2009294290B2 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
MX2011002899A MX2011002899A (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy. |
JP2011527444A JP2012502975A (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
EA201100368A EA201100368A1 (en) | 2008-09-18 | 2009-09-16 | AMIDA CONNECTIONS USEFUL IN THERAPY |
EP09787204A EP2350017A1 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
BRPI0918935A BRPI0918935A2 (en) | 2008-09-18 | 2009-09-16 | amide compounds useful in therapy |
AP2011005611A AP2011005611A0 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy. |
CA2735931A CA2735931A1 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
CN2009801364939A CN102159548A (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
IL211479A IL211479A0 (en) | 2008-09-18 | 2011-02-28 | Amide compounds useful in therapy |
TN2011000131A TN2011000131A1 (en) | 2009-09-16 | 2011-03-14 | USEFUL AMIDES IN THERAPY |
MA33710A MA32642B1 (en) | 2008-09-18 | 2011-03-18 | Amides are useful in treatment |
ZA2011/02690A ZA201102690B (en) | 2008-09-18 | 2011-04-11 | Amide compounds useful in therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9790208P | 2008-09-18 | 2008-09-18 | |
US61/097,902 | 2008-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010032200A1 true WO2010032200A1 (en) | 2010-03-25 |
Family
ID=41269630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/054038 WO2010032200A1 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
Country Status (20)
Country | Link |
---|---|
US (2) | US8232269B2 (en) |
EP (1) | EP2350017A1 (en) |
JP (1) | JP2012502975A (en) |
KR (1) | KR20110044304A (en) |
CN (1) | CN102159548A (en) |
AP (1) | AP2011005611A0 (en) |
AU (1) | AU2009294290B2 (en) |
BR (1) | BRPI0918935A2 (en) |
CA (1) | CA2735931A1 (en) |
CL (1) | CL2011000570A1 (en) |
CO (1) | CO6351734A2 (en) |
DO (1) | DOP2011000083A (en) |
EA (1) | EA201100368A1 (en) |
EC (1) | ECSP11010901A (en) |
IL (1) | IL211479A0 (en) |
MA (1) | MA32642B1 (en) |
MX (1) | MX2011002899A (en) |
PE (1) | PE20110793A1 (en) |
WO (1) | WO2010032200A1 (en) |
ZA (1) | ZA201102690B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2700635A1 (en) | 2012-08-20 | 2014-02-26 | Basf Se | 5-Trifluoromethylpyrazole amides having herbicidal activity |
JP2014511895A (en) * | 2011-04-21 | 2014-05-19 | オリオン コーポレーション | Androgen receptor modulating carboxamide |
WO2014128591A1 (en) | 2013-02-22 | 2014-08-28 | Pfizer Inc. | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
US20140303160A1 (en) * | 2011-07-21 | 2014-10-09 | The Regents Of The University Of California | Targeting GLI Proteins in Human Cancer by Small Molecules |
WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
US9416109B2 (en) | 2012-02-17 | 2016-08-16 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
US9840470B2 (en) | 2013-01-23 | 2017-12-12 | The Regents Of The University Of California | Targeting GLI proteins in human cancer by small molecules |
WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014143617A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Women's Health, Inc. | Deuterium-enriched tanaproget and processes for its preparation |
CN108623446A (en) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | A kind of method of synthesis 3,3- difluoro cyclobutane formates |
KR20220100607A (en) * | 2019-10-28 | 2022-07-15 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 5-membered heterocyclic oxocarboxylic acid compound and its medicinal use |
CN118660877A (en) * | 2022-05-12 | 2024-09-17 | 西北农林科技大学 | Preparation method of diphenyl pyrazole compound |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006111856A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080066938A (en) * | 2005-10-07 | 2008-07-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
-
2009
- 2009-09-16 CN CN2009801364939A patent/CN102159548A/en active Pending
- 2009-09-16 EP EP09787204A patent/EP2350017A1/en not_active Withdrawn
- 2009-09-16 BR BRPI0918935A patent/BRPI0918935A2/en not_active IP Right Cessation
- 2009-09-16 JP JP2011527444A patent/JP2012502975A/en not_active Withdrawn
- 2009-09-16 MX MX2011002899A patent/MX2011002899A/en not_active Application Discontinuation
- 2009-09-16 AU AU2009294290A patent/AU2009294290B2/en not_active Expired - Fee Related
- 2009-09-16 WO PCT/IB2009/054038 patent/WO2010032200A1/en active Application Filing
- 2009-09-16 PE PE2011000628A patent/PE20110793A1/en not_active Application Discontinuation
- 2009-09-16 AP AP2011005611A patent/AP2011005611A0/en unknown
- 2009-09-16 CA CA2735931A patent/CA2735931A1/en not_active Abandoned
- 2009-09-16 EA EA201100368A patent/EA201100368A1/en unknown
- 2009-09-16 KR KR1020117006161A patent/KR20110044304A/en not_active Application Discontinuation
- 2009-09-17 US US12/561,398 patent/US8232269B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 IL IL211479A patent/IL211479A0/en unknown
- 2011-03-17 CL CL2011000570A patent/CL2011000570A1/en unknown
- 2011-03-17 DO DO2011000083A patent/DOP2011000083A/en unknown
- 2011-03-17 EC EC2011010901A patent/ECSP11010901A/en unknown
- 2011-03-18 MA MA33710A patent/MA32642B1/en unknown
- 2011-03-25 CO CO11036952A patent/CO6351734A2/en not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02690A patent/ZA201102690B/en unknown
-
2012
- 2012-06-18 US US13/525,893 patent/US20120316150A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006111856A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014511895A (en) * | 2011-04-21 | 2014-05-19 | オリオン コーポレーション | Androgen receptor modulating carboxamide |
US9370521B2 (en) * | 2011-07-21 | 2016-06-21 | The Regents Of The University Of California | Targeting GLI proteins in human cancer by small molecules |
US20140303160A1 (en) * | 2011-07-21 | 2014-10-09 | The Regents Of The University Of California | Targeting GLI Proteins in Human Cancer by Small Molecules |
US9416109B2 (en) | 2012-02-17 | 2016-08-16 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
US9828336B2 (en) | 2012-02-17 | 2017-11-28 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
EP2700635A1 (en) | 2012-08-20 | 2014-02-26 | Basf Se | 5-Trifluoromethylpyrazole amides having herbicidal activity |
US9840470B2 (en) | 2013-01-23 | 2017-12-12 | The Regents Of The University Of California | Targeting GLI proteins in human cancer by small molecules |
US9545405B2 (en) | 2013-02-22 | 2017-01-17 | Pfizer Inc. | Pyrrolo[2,3-D]pyrimidine derivatives |
WO2014128591A1 (en) | 2013-02-22 | 2014-08-28 | Pfizer Inc. | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
US9549929B2 (en) | 2013-02-22 | 2017-01-24 | Pfizer Inc. | Pyrrolo[2,3-D]pyrimidine derivatives |
US9035074B2 (en) | 2013-02-22 | 2015-05-19 | Pfizer Inc. | Pyrrolo[2,3-D]pyrimidine derivatives |
EP3290421A1 (en) | 2013-02-22 | 2018-03-07 | Pfizer Inc | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) |
WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
US10966980B2 (en) | 2014-08-12 | 2021-04-06 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives |
WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
Also Published As
Publication number | Publication date |
---|---|
EA201100368A1 (en) | 2011-12-30 |
KR20110044304A (en) | 2011-04-28 |
CN102159548A (en) | 2011-08-17 |
CA2735931A1 (en) | 2010-03-25 |
PE20110793A1 (en) | 2011-10-31 |
EP2350017A1 (en) | 2011-08-03 |
ECSP11010901A (en) | 2011-04-29 |
US20120316150A1 (en) | 2012-12-13 |
JP2012502975A (en) | 2012-02-02 |
AU2009294290B2 (en) | 2012-08-30 |
BRPI0918935A2 (en) | 2015-12-01 |
MA32642B1 (en) | 2011-09-01 |
AU2009294290A1 (en) | 2010-03-25 |
US8232269B2 (en) | 2012-07-31 |
AP2011005611A0 (en) | 2011-04-30 |
DOP2011000083A (en) | 2011-03-31 |
MX2011002899A (en) | 2011-04-11 |
US20100249091A1 (en) | 2010-09-30 |
CL2011000570A1 (en) | 2011-06-17 |
CO6351734A2 (en) | 2011-12-20 |
IL211479A0 (en) | 2011-05-31 |
ZA201102690B (en) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009294290B2 (en) | Amide compounds useful in therapy | |
NL1031626C2 (en) | Compounds useful in therapy. | |
EP1948615B1 (en) | Pyrazole derivatives useful for the treatment of gynaecological diseases | |
AU2008249744A1 (en) | Azetidine derivatives and their use as prostaglandin E2 antagonists | |
AU2009312427B2 (en) | Pyrrolidines | |
WO2008047224A1 (en) | Pyrazolyl-4-oxy-benzonitrile derivatives useful in treating endometriosis | |
CA2705368A1 (en) | Azetidines as ep2 antagonists | |
WO2008135824A1 (en) | Oxyalkylpyrazole compounds useful in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980136493.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09787204 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 211479 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009294290 Country of ref document: AU Ref document number: 591474 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2735931 Country of ref document: CA Ref document number: 2009787204 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000124 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2011527444 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201100368 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000628-2011 Country of ref document: PE Ref document number: DZP2011000200 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011500556 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 20117006161 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011000570 Country of ref document: CL Ref document number: D2011056 Country of ref document: CU Ref document number: MX/A/2011/002899 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12146 Country of ref document: GE Ref document number: 2041/DELNP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009294290 Country of ref document: AU Date of ref document: 20090916 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11036952 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201102263 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: PI0918935 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110317 |